identifier	name	definition	synonyms	alts	parents	species
1	ALK	ALK amplifications, fusions and mutations have been shown to be driving events in non-small cell lung cancer. While crizontinib has demonstrated efficacy in treating the amplification, mutations in ALK have been shown to confer resistance to current tyrosine kinase inhibitors. Second-generation TKI's have seen varied success in treating these resistant cases, and the HSP90 inhibitor 17-AAG has been shown to be cytostatic in ALK-altered cell lines.	ALK1|CD246|NBLST3		obo:civic.gid#gene	
10	CCND3	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. Cyclin D3 loss has been reported in T-ALL, a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. In a mouse study, the targeted therapeutic palbociclib significantly increased the median survival of the cyclin D3 knockouts.			obo:civic.gid#gene	
10024	SETBP1		MRD29|SEB		obo:civic.gid#gene	
101	ABL2		ABLL|ARG		obo:civic.gid#gene	
10239	DAZAP1				obo:civic.gid#gene	
10573	PDCD4		H731		obo:civic.gid#gene	
11	CCNE1	Cyclin E, while currenly not as widely implicated as its cyclin D counterparts, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, have been shown to lead to poorer prognosis in gastic carcinoma, and these measurements are correlated with later stage disease. In lung cancer, neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their more lowly expressed counterparts.	CCNE|pCCNE1		obo:civic.gid#gene	
11261	MAGEH1		APR-1|APR1|MAGEH		obo:civic.gid#gene	
11289	SETD2		HBP231|HIF-1|HIP-1|HSPC069|HYPB|KMT3A|LLS|MRD70|RAPAS|SET2|p231HBP		obo:civic.gid#gene	
11314	DROSHA		ETOHI2|HSA242976|RANSE3L|RN3|RNASE3L|RNASEN		obo:civic.gid#gene	
11322	TBK1		AIARV|FTDALS4|IIAE8|NAK|T2K		obo:civic.gid#gene	
11335	CD274	CD274, also commonly referred to as PDL1, is a ligand that binds with the receptor PD1, commonly found on T-cells, and acts to block T-cell activation. PD1 expression has been observed in a variety of cancers including melanoma and non-small cell lung cancer. The interaction of PD1/PDL1 is hypothesized to be a possible mechanism for the tumor to escape immune response. A number of checkpoint blockade inhibitors including pembrolizumab and nivolumab have been developed that target the PD1/PDL1 interaction in order to allow T-cells to recognize tumor cells without being deactivated by the tumor.	B7-H|B7H1|PD-L1|PDCD1L1|PDCD1LG1|PDL1|hPD-L1		obo:civic.gid#gene	
11492	CTAG2		CAMEL|CT2|CT6.2|CT6.2a|CT6.2b|ESO2|LAGE-1|LAGE2B		obo:civic.gid#gene	
11587	FOXP3		AIID|DIETER|IPEX|JM2|PIDX|XPID		obo:civic.gid#gene	
11761	CRBN		MRT2|MRT2A		obo:civic.gid#gene	
11781	CLDN18		SFTA5|SFTPJ		obo:civic.gid#gene	
11900	UBR5		DD5|EDD|EDD1|HYD		obo:civic.gid#gene	
1193	CREBBP		CBP|KAT3A|MKHK1|RSTS|RSTS1		obo:civic.gid#gene	
11932	DDX41		ABS|MPLPF		obo:civic.gid#gene	
12	CDK6	CDK6, along with its partner CDK4, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	MCPH12|PLSTIRE		obo:civic.gid#gene	
1204	CRKL				obo:civic.gid#gene	
12074	SUFU		BCNS2|JBTS32|PRO1280|SUFUH|SUFUXL		obo:civic.gid#gene	
12112	CDK12		CRK7|CRKR|CRKRS		obo:civic.gid#gene	
12121	RSF1		HBXAP|RSF-1|XAP8|p325		obo:civic.gid#gene	
12133	BCL11A		CTIP1|DILOS|EVI9|HBFQTL5|SMARCM1|ZNF856		obo:civic.gid#gene	
12146	LRP1B	LRP1B is a putative tumor suppressor and a member of the low-density lipoprotein (LDL) receptor family. The LDL receptor family have roles related to clearance of extracellular ligand and are proposed to be involved in extracellular signal transduction. silencing and down-expression of LRP1B as been observed in renal cell carcinoma and thyroid cancer. Further Deletion of LRP1B has been associated with chemotherapy resistance in high-grade serous cancers.	LRP-1B|LRP-DIT|LRPDIT		obo:civic.gid#gene	
12271	ERRFI1		GENE-33|MIG-6|MIG6|RALT		obo:civic.gid#gene	
1234	CSF1		CSF-1|MCSF|PG-M-CSF		obo:civic.gid#gene	
12367	ROBO4		AOVD3|ECSM4|MRB		obo:civic.gid#gene	
1239	CSF3R		CD114|GCSFR|SCN7		obo:civic.gid#gene	
12422	UGT1A1		BILIQTL1|GNT1|HUG-BR1|UDPGT|UDPGT 1-1|UGT1|UGT1A		obo:civic.gid#gene	
12555	BCOR		ANOP2|MAA2|MCOPS2		obo:civic.gid#gene	
12754	FANCL		FAAP43|PHF9|POG		obo:civic.gid#gene	
1278	CTAG1B		CT6.1|CTAG|CTAG1|ESO1|LAGE-2|LAGE2B|NY-ESO-1		obo:civic.gid#gene	
128	ACTA1		ACTA|ASMA|CFTD|CFTD1|CFTDM|CMYO2A|CMYO2B|CMYO2C|CMYP2A|CMYP2B|CMYP2C|MPFD|NEM1|NEM2|NEM3|SHPM		obo:civic.gid#gene	
1283	CCN2		CTGF|HCS24|IBP-8|IGFBP8|NOV2		obo:civic.gid#gene	
1285	CTLA4		ALPS5|CD|CD152|CELIAC3|CTLA-4|GRD4|GSE|IDDM12		obo:civic.gid#gene	
12881	NUDT15		MTH2|NUDT15D		obo:civic.gid#gene	
1290	CTNNB1		CTNNB|EVR7|MRD19|NEDSDV|armadillo		obo:civic.gid#gene	
12903	FBXW7		AGO|CDC4|DEDHIL|FBW6|FBW7|FBX30|FBXO30|FBXW6|SEL-10|SEL10|hAgo|hCdc4		obo:civic.gid#gene	
13	CDK4	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.	CMM3|PSK-J3		obo:civic.gid#gene	
130	ACTB		BKRNS|BNS|BRWS1|CSMH|DDS1|PS1TP5BP1|THC8		obo:civic.gid#gene	
13005	DDX43		CT13|HAGE		obo:civic.gid#gene	
13180	TMEM30A		C6orf67|CDC50A		obo:civic.gid#gene	
13185	WDR12		YTM1		obo:civic.gid#gene	
13276	PBK		CT84|HEL164|Nori-3|SPK|TOPK		obo:civic.gid#gene	
1342	CYP2D6		CPD6|CYP2D|CYP2D7AP|CYP2D7BP|CYP2D7P2|CYP2D8P2|CYP2DL1|CYPIID6|P450-DB1|P450C2D|P450DB1		obo:civic.gid#gene	
13465	POLE4		YHHQ1|p12		obo:civic.gid#gene	
13556	EMSY		C11orf30|GL002		obo:civic.gid#gene	
13648	CYSLTR2		CYSLT2|CYSLT2R|GPCR21|HG57|HPN321|KPG_011|PSEC0146|hGPCR21		obo:civic.gid#gene	
13783	BIRC6		APOLLON|BRUCE		obo:civic.gid#gene	
13880	KLHL14				obo:civic.gid#gene	
1390	DBI		ACBD1|ACBP|CCK-RP|EP		obo:civic.gid#gene	
13948	CIP2A		KIAA1524|NOCIVA|p90		obo:civic.gid#gene	
1396	DCC		CRC18|CRCR1|HGPPS2|IGDCC1|MRMV1|NTN1R1		obo:civic.gid#gene	
13968	CHD8		AUTS18|HELSNF1|IDDAM		obo:civic.gid#gene	
14	CDKN2A	CDKN2A loss has been shown to be a significant event in a number of cancer types. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. In majority of cases CDKN2A is inactivated by homozygous deletions. One of the mechanisms by which loss of CDKN2A can occur is by hypermethylation of the promoter region for the gene. However, the prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have suggesting poorer prognostic outcome for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator. Additionally, CDKN2A (p16) expression is a surrogate marker for HPV infection. As such, CDKN2A expression is prognostic in Oropharyngeal and probably also non-oropharyngeal head and neck squamous cell carcinomas.	ARF|CAI2|CDK4I|CDKN2|CMM2|INK4|INK4A|MLM|MTS-1|MTS1|P14|P14ARF|P16|P16-INK4A|P16INK4|P16INK4A|P19|P19ARF|TP16		obo:civic.gid#gene	
14079	OVOL2		CHED|CHED1|CHED2|EUROIMAGE566589|PPCD1|ZNF339		obo:civic.gid#gene	
14089	KMT2C		HALR|KLEFS2|MLL3		obo:civic.gid#gene	
1411	GADD45A		DDIT1|GADD45		obo:civic.gid#gene	
14160	BACH2		BTBD25|IMD60		obo:civic.gid#gene	
1417	DDX3X		CAP-Rf|DBX|DDX14|DDX3|HLP2|MRX102|MRXSSB		obo:civic.gid#gene	
14195	PAPPA2		PAPP-A2|PAPP-E|PAPPE|PLAC3|SSDA		obo:civic.gid#gene	
1428	DEFA1		DEF1|DEFA2|HNP-1|HP-1|HP1|MRS		obo:civic.gid#gene	
14284	PBLD		HEL-S-306|MAWBP|MAWDBP		obo:civic.gid#gene	
14303	CRLF2		CRL2|CRLF2Y|TSLPR		obo:civic.gid#gene	
14368	NFKBIZ		I-kappa-B-zeta|IKBZ|INAP|IkappaB-zeta|MAIL|ikB-zeta|ikappaBzeta		obo:civic.gid#gene	
14525	RFX7		MRD71|RFXDC2		obo:civic.gid#gene	
14591	WNK1		HSAN2|HSN2|KDP|PPP1R167|PRKWNK1|PSK|p65		obo:civic.gid#gene	
1463	NQO1		DHQU|DIA4|DTD|NMOR1|NMORI|QR1		obo:civic.gid#gene	
14842	BIRC7	BIRC7 encodes the protein Livin which is a member of the inhibitor of apoptosis protein (IAP) family. Livin consists of a single baculoviral IAP repeat domain (BIR) and a RING domian at the C-terminus. The protein inhibits apoptosis by inhibiting proteolytic activation of capsases. Overexpression of Livin has been observed in a variety of cancers including lung, colon, and prostate compared to most normal adult tissues and has been proposed as a putative therapeutic target.	KIAP|LIVIN|ML-IAP|MLIAP|RNF50		obo:civic.gid#gene	
14923	GALNT14		GALNT15|GalNac-T10|GalNac-T14		obo:civic.gid#gene	
14995	NOL9		Grc3|NET6		obo:civic.gid#gene	
15	CEBPA	'AML with mutated CEBPA' is a provisional entity in the WHO classification of acute myeloid leukemia (AML) and is recommended to be tested for in patients with AML. CEBPA mutations are particularly associated with cytogenetically normal AML (CN-AML). CEBPA is an intronless gene that is required for granulocyte formation in mice. N-terminal nonsense mutations result in a dominant negative C/EBP-alpha protein while C-terminal mutations reduce the DNA-binding potential of this transcription factor. CEBPA mutations are associated with a favorable prognosis, however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.	C/EBP-alpha|CEBP		obo:civic.gid#gene	
150	ACTL6A		ACTL6|ARPN-BETA|Arp4|BAF53A|INO80K|SMARCN1		obo:civic.gid#gene	
15004	TBL1XR1		C21|DC42|IRA1|MRD41|TBLR1		obo:civic.gid#gene	
15013	PALB2		BROVCA5|FANCN|PNCA3		obo:civic.gid#gene	
1510	DNMT1		ADCADN|AIM|CXXC9|DNMT|HSN1E|MCMT|m.HsaI		obo:civic.gid#gene	
1526	DPYD		DHP|DHPDHASE|DPD|DYPD		obo:civic.gid#gene	
15315	MUS81		SLX3		obo:civic.gid#gene	
15318	FBXO11		FBX11|IDDFBA|PRMT9|UBR6|UG063H01|VIT1		obo:civic.gid#gene	
15344	PREX2		DEP.2|DEPDC2|P-REX2|PPP1R129		obo:civic.gid#gene	
1536	DRD5		DBDR|DRD1B|DRD1L2		obo:civic.gid#gene	
15369	TET1		CXXC6|LCX|bA119F7.1		obo:civic.gid#gene	
154	ACVR1		ACTRI|ACVR1A|ACVRLK2|ALK2|FOP|SKR1|TSRI		obo:civic.gid#gene	
15403	PDCD1LG2		B7DC|Btdc|CD273|PD-L2|PDCD1L2|PDL2|bA574F11.2		obo:civic.gid#gene	
1559	DTX1		RNF140|hDx-1		obo:civic.gid#gene	
1563	DUSP2		PAC-1|PAC1		obo:civic.gid#gene	
1567	DUSP6		HH19|MKP3|PYST1		obo:civic.gid#gene	
15676	NECTIN4		EDSS1|LNIR|PRR4|PVRL4|nectin-4		obo:civic.gid#gene	
1590	EBF1		COE1|EBF|O/E-1|OLF1		obo:civic.gid#gene	
15955	BRIP1		BACH1|FANCJ|OF		obo:civic.gid#gene	
1603	S1PR1		CD363|CHEDG1|D1S3362|ECGF1|EDG-1|EDG1|S1P1		obo:civic.gid#gene	
16160	HVCN1		HV1|VSOP		obo:civic.gid#gene	
16180	CARD11		BENTA|BIMP3|CARMA1|IMD11|IMD11A|PPBL		obo:civic.gid#gene	
1627	EFNA2		ELF-1|EPLG6|HEK7-L|LERK-6|LERK6		obo:civic.gid#gene	
1634	EGF		HOMG4|URG		obo:civic.gid#gene	
16394	HAVCR2		CD366|HAVcr-2|KIM-3|SPTCL|TIM3|TIMD-3|TIMD3|Tim-3		obo:civic.gid#gene	
1646	EIF1AX		EIF1A|EIF1AP1|EIF4C|eIF-1A|eIF-4C		obo:civic.gid#gene	
1651	EIF4A1		DDX2A|EIF-4A|EIF4A|eIF-4A-I|eIF4A-I		obo:civic.gid#gene	
16516	H2BC12		H2B/S|H2BFAiii|H2BFT|H2BK|HIST1H2BK		obo:civic.gid#gene	
1655	EIF4EBP1		4E-BP1|4EBP1|BP-1|PHAS-I		obo:civic.gid#gene	
16656	ABCC10		EST182763|MRP7|SIMRP7		obo:civic.gid#gene	
16661	KLHL6				obo:civic.gid#gene	
16802	IL33		C9orf26|DVS27|IL1F11|NF-HEV|NFEHEV		obo:civic.gid#gene	
16872	SLFN11		SLFN8/9		obo:civic.gid#gene	
16939	RCSD1		CAPZIP|MK2S4		obo:civic.gid#gene	
1701	SLC29A1		AUG|ENT1|hENT1		obo:civic.gid#gene	
17016	NAPRT		NAPRT1|PP3856		obo:civic.gid#gene	
1704	EP300		KAT3B|MKHK2|RSTS2|p300		obo:civic.gid#gene	
1705	EPAS1		ECYT4|HIF2A|HLF|MOP2|PASD2|bHLHe73		obo:civic.gid#gene	
1719	EPHB2		BDPLT22|CAPB|DRT|EK5|EPHT3|ERK|Hek5|PCBC|Tyro5		obo:civic.gid#gene	
1721	EPHB4		CMAVM2|HFASD|HTK|LMPHM7|MYK1|TYRO11		obo:civic.gid#gene	
1728	EPOR		EPO-R		obo:civic.gid#gene	
1733	ERBB3		ErbB-3|FERLK|HER3|LCCS2|MDA-BF-1|VSCN1|c-erbB-3|c-erbB3|erbB3-S|p180-ErbB3|p45-sErbB3|p85-sErbB3		obo:civic.gid#gene	
1734	ERBB4	ErbB4 (HER4) is one of the four members in the EGFR subfamily of receptor tyrosine kinases. Ligands include EGF, epiregulin, betacellulin and the neuregulins (Sundvall et. al.). Of these, NRG3 and NRG4 exclusively bind HER4 (Hynes et. al.). Mutations in ERBB4 have been identified in various cancer types including melanoma, lung adenocarcinoma and medulloblastoma. A therapeutic value of these aberrations still remains unknown (Arteaga et. al.).	ALS19|HER4|p180erbB4		obo:civic.gid#gene	
17340	OSBPL10		ORP10|OSBP9		obo:civic.gid#gene	
1735	ERCC1		COFS4|RAD10|UV20		obo:civic.gid#gene	
1736	ERCC2	ERCC2 functions as a DNA repair gene involved in separating the double helix via 5’-3’ helicase activity. It forms a part of the transcription factor II Human (TFIIH) complex and is ATP-dependent. The TFIIH complex is known to be involved in the nucleotide excision repair pathway (NER) which can repair DNA damage caused by chemotherapeutic treatment and basal transcription. ERCC2 variants have been observed in a variety of cancers. A number of studies have suggested ERCC2 variants can act as biomarkers to predict response to neoadjuvant treatment, and cancer prognosis. Additionally the Lys751Gln polymorphism has been observed to increase risk in a number of cancer types; however, results have been conflicting.	COFS2|EM9|TFIIH|TTD|TTD1|XPD		obo:civic.gid#gene	
1737	EREG		EPR|ER|Ep		obo:civic.gid#gene	
1741	ERCC5		COFS3|ERCC5-201|ERCM2|UVDR|XPG|XPGC		obo:civic.gid#gene	
1742	ERCC6		ARMD5|CKN2|COFS|COFS1|CSB|CSB-PGBD3|POF11|RAD26|UVSS1		obo:civic.gid#gene	
1753	ESR2		ER-BETA|ESR-BETA|ESRB|ESTRB|Erb|NR3A2|ODG8		obo:civic.gid#gene	
1762	ETS1		ETS-1|EWSR2|c-ets-1|p54		obo:civic.gid#gene	
1763	ETS2		ETS2IT1		obo:civic.gid#gene	
1764	ETV1		ER81		obo:civic.gid#gene	
1767	ETV4		E1A-F|E1AF|PEA3|PEAS3		obo:civic.gid#gene	
1768	ETV5		ERM		obo:civic.gid#gene	
1769	ETV6		TEL|TEL/ABL|THC5		obo:civic.gid#gene	
1771	MECOM		AML1-EVI-1|EVI1|KMT8E|MDS1|MDS1-EVI1|PRDM3|RUSAT2		obo:civic.gid#gene	
17939	H3C14		H3|H3.2|H3/M|H3C13|H3C15|H3F2|H3FM|H3FN|HIST2H3C		obo:civic.gid#gene	
18	DNMT3A	DNMT3A is one of several epigenetic modifiers identified as recurrently mutated in acute myeloid leukemia (AML). DNMT3A mutations are associated with cytogenetically normal AML. In vitro experiments indicate that the R882H mutation acts in a dominant negative manner to disrupt the de novo methyltransferase activity of wildtype homotetramers. AML patient bone marrow harboring R882 mutations were similarly demonstrated to be hypomethylated compared to patients with wildtype DNMT3A. These studies also indicated that non-R882 DNMT3A mutations may act in a functionally distinct manner from R882 mutations. Alternative mechanisms indicate independent prognostic outcomes and treatment protocols may need to be considered for these two classes of DNMT3A mutations.	DNMT3A2|HESJAS|M.HsaIIIA|TBRS		obo:civic.gid#gene	
1810	FANCA		FA|FA-H|FA1|FAA|FACA|FAH|FANCH		obo:civic.gid#gene	
1811	FANCC		FA3|FAC|FACC		obo:civic.gid#gene	
1827	FAT1		CDHF7|CDHR8|FAT|ME5|hFat1		obo:civic.gid#gene	
18353	VPS37A		HCRP1|PQBP2|SPG53		obo:civic.gid#gene	
18364	PXDNL		PMR1|PRM1|VPO2		obo:civic.gid#gene	
1842	FCGR2A		CD32|CD32A|CDw32|FCG2|FCGR2|FCGR2A1|FcGR|FcgammaRIIa|IGFR2		obo:civic.gid#gene	
18420	AMER1		FAM123B|OSCS|WTX		obo:civic.gid#gene	
1843	FCGR2B		CD32|CD32B|FCG2|FCGR2|FCGR2C|FcGRIIB|FcRII-c|FcgammaRIIb|IGFR2		obo:civic.gid#gene	
1844	FCGR3A		CD16|CD16-II|CD16A|FCG3|FCGR3|FCGRIII|FCR-10|FCRIII|FCRIIIA|FcGRIIIA|IGFR3|IMD20		obo:civic.gid#gene	
18440	FOXR2		FOXN6		obo:civic.gid#gene	
1872	FGF2		BFGF|FGF-2|FGFB|HBGF-2		obo:civic.gid#gene	
1873	FGF3	FGF3 is a member of the basic fibroblast growth factor (FGF) gene family and was first identified based on it's similarity to the mouse proto-oncogene int-2. Amplifications of this gene and the surrounding region (11q13) have been observed in various cancers including breast cancer, esophogeal cancer, melanoma, bladder cancer and hepatocellular carcinoma (HCC). Lower tumor grade and stage have been associated with FGF3 amplifications in HCC; however, this event is fairly rare in this tumor type.	HBGF-3|INT2		obo:civic.gid#gene	
1883	FGF13		DEE90|FGF-13|FGF2|FHF-2|FHF2|LINC00889|XLID110		obo:civic.gid#gene	
1885	FGFR1	FGFR1 is a member of the Fibroblast Growth Factor family, comprising of 4 receptors and 18 Ligands. FGFR1 signalling downstream functions mainly via PI3K and MAPK pathways (Turner et. al.). Several ways of involvement of FGFR1 in cancer have been proposed: auto- and paracrine activation, amplification and overexpression (Marshall et. al, Weiss et. al., Cheng et. al.). Especially amplification of FGFR1 in lung cancer is an emerging treatment target with clinical studies currently ongoing (e.g. NCT01004224). However, FGFR1 amplification does not always correlate with protein expression and predictive biomarkers still remain to be defined in clinic (von Mässenhausen et. al.). Mutation of FGFR1 seems to be less common, but has been described in glioblastoma, pilocytic astrocytomas and Ewing's sarcoma (Rand et. al., Jones et. al., Agelopoulos et. al.).	BFGFR|CD331|CEK|ECCL|FGFBR|FGFR-1|FLG|FLT-2|FLT2|HBGFR|HH2|HRTFDS|KAL2|N-SAM|OGD|bFGF-R-1		obo:civic.gid#gene	
1887	FGFR4		CD334|JTK2|TKF		obo:civic.gid#gene	
19	EGFR	EGFR is widely recognized for its importance in cancer. Amplification and mutations have been shown to be driving events in many cancer types. Its role in non-small cell lung cancer, glioblastoma and basal-like breast cancers has spurred many research and drug development efforts. Tyrosine kinase inhibitors have shown efficacy in EGFR amplfied tumors, most notably gefitinib and erlotinib. Mutations in EGFR have been shown to confer resistance to these drugs, particularly the variant T790M, which has been functionally characterized as a resistance marker for both of these drugs. The later generation TKI's have seen some success in treating these resistant cases, and targeted sequencing of the EGFR locus has become a common practice in treatment of non-small cell lung cancer. Overproduction of ligands is another possible mechanism of activation of EGFR. ERBB ligands include EGF, TGF-a, AREG, EPG, BTC, HB-EGF, EPR and NRG1-4 (for detailed information please refer to the respective ligand section).	ERBB|ERBB1|ERRP|HER1|NISBD2|PIG61|mENA		obo:civic.gid#gene	
1911	FOXF1		ACDMPV|FKHL5|FREAC1		obo:civic.gid#gene	
1920	FOXC2		FKHL14|LD|MFH-1|MFH1		obo:civic.gid#gene	
1925	FOXO1		FKH1|FKHR|FOXO1A		obo:civic.gid#gene	
1926	FOXO3		AF6q21|FKHRL1|FKHRL1P2|FOXO2|FOXO3A		obo:civic.gid#gene	
1937	FLT3LG		FL|FLG3L|FLT3L		obo:civic.gid#gene	
1938	FLT4		CHTD7|FLT-4|FLT41|LMPH1A|LMPHM1|PCL|VEGFR-3|VEGFR3		obo:civic.gid#gene	
1947	FN1		CIG|ED-B|FINC|FN|FNZ|GFND|GFND2|LETS|MSF|SMDCF		obo:civic.gid#gene	
1950	FNTB		FPTB		obo:civic.gid#gene	
1955	FOS		AP-1|C-FOS|p55		obo:civic.gid#gene	
1956	FOSB		AP-1|G0S3|GOS3|GOSB		obo:civic.gid#gene	
19838	ARID2		BAF200|CSS6|SMARCF3|ZIPZAP|p200		obo:civic.gid#gene	
19896	FAAP20		C1orf86|FP7162		obo:civic.gid#gene	
199	PARP1		ADPRT|ADPRT 1|ADPRT1|ARTD1|PARP|PARP-1|PARS|PPOL|Poly-PARP|pADPRT-1		obo:civic.gid#gene	
19959	FLCN		BHD|DENND8B|FLCL		obo:civic.gid#gene	
2	AKT1	AKT1, also referred to as protein kinase B, is a known oncogene. AKT activation relies on the PI3K pathway, and is recognized as a critical node in the pathway. The E17 hotspot is the most characterized of AKT1 mutations, and has been shown to result in activation of the protein. Mutations in AKT1 have also been shown to confer resistance to allosteric kinase inhibitors in vitro.	AKT|PKB|PKB-ALPHA|PRKBA|RAC|RAC-ALPHA		obo:civic.gid#gene	
20	ERBB2	ERBB2, commonly referred to as HER2, is amplified and/or overexpressed in 20-30% of invasive breast carcinomas. HER2-positive breast cancer is treated in a separate manner from other subtypes of breast cancer and commonly presents as more aggressive disease. Metastatic HER2-positive breast cancer is now commonly treated with HER2-targeted therapy. Apart from being amplified/overexpressed, ERBB2 activating mutations have been shown to have clinical importance in HER2-negative breast cancer. These mutations have shown sensitivity to the tyrosine kinase inhibitor neratinib, and highlight the importance of clinical sequencing efforts in treating breast cancer.	CD340|HER-2|HER-2/neu|HER2|MLN 19|MLN-19|NEU|NGL|TKR1|VSCN2|c-ERB-2|c-ERB2|p185(erbB2)		obo:civic.gid#gene	
20168	MPEG1		IMD77|MPG1|MPS1|Mpg-1|P-2		obo:civic.gid#gene	
20480	RICTOR		AVO3|PIA|hAVO3		obo:civic.gid#gene	
2073	MTOR	mTOR deregulation has been observed in many cancer types. As a part of the PI3K/Akt pathway, there is a broad interest in mTOR biology across cancer types. mTOR inhibition has been investigated for nearly a decade. Everolimus, temsirolimus and zotarolimus are three of the more commonly used mTOR inhibitors used in clinical treatment today, with modest success.	FRAP|FRAP1|FRAP2|RAFT1|RAPT1|SKS		obo:civic.gid#gene	
21	ESR1	ESR1 has been a focus in breast cancer for quite some time, but is also clinically relevant in endometrial, ovarian and other cancer types. The identification of ER-positive breast cancers that are resistant to hormone therapy have inspired clinical sequencing efforts to shed light on the mechanisms of this resistance. A number of mutations in the ligand binding domain of ESR1 have been implicated in hormone resistance and anti-estrogen therapies. These observations have spurred efforts to develop therapeutics that stimulate ESR1 protein degradation (e.g. Fulvestrant), rather than acting as a small molecule antagonist. These agents are currently in clinical trials and have seen some success.	ER|ESR|ESRA|ESTRR|Era|NR3A1		obo:civic.gid#gene	
21380	RABL3		PNCA5		obo:civic.gid#gene	
21634	P2RY8		P2Y8		obo:civic.gid#gene	
2186	GAS6		AXLLG|AXSF		obo:civic.gid#gene	
2188	GATA1		ERYF1|GATA-1|GF-1|GF1|HAEADA|NF-E1|NFE1|XLANP|XLTDA|XLTT		obo:civic.gid#gene	
2189	GATA3		HDR|HDRS		obo:civic.gid#gene	
22	FGFR2	The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.	BBDS|BEK|BFR-1|CD332|CEK3|CFD1|ECT1|JWS|K-SAM|KGFR|TK14|TK25		obo:civic.gid#gene	
221	AEBP1		ACLP		obo:civic.gid#gene	
22231	ATXN1L		BOAT|BOAT1		obo:civic.gid#gene	
2239	B4GALT1		B4GAL-T1|CDG2D|CLDLFIB|GGTB2|GT1|GTB|beta4Gal-T1		obo:civic.gid#gene	
23	FGFR3	The FGFR proteins are involved in a wide array of pathways known to play a signficant role in cancer. Activation of these receptors can lead to activation of the RAS-MAPK pathway and the PI3K-AKT pathway, among others. The mechanisms by which FGFR can be misregulated vary between cancers. Amplification of the receptors has been observed in lung and breast cancers, coding mutations and deletions have been seen in many cancers, and more recently, FGFR fusions that lead to pathway actiation have been demonstrated to have oncogenic potential across multiple cancer types. The targeted therapeutics ponatinib, dovitinib and pazopanib have seen success in treating over-active FGFR signalling, prompting use of diagnostic sequencing targeting the FGFR genes, especially in lung cancer patients.	ACH|CD333|CEK2|HSFGFR3EX|JTK4		obo:civic.gid#gene	
2308	GNA11		FBH|FBH2|FHH2|GNA-11|HG1K|HHC2|HYPOC2		obo:civic.gid#gene	
2312	GNAI2		GIP|GNAI2B|HG1C|H_LUCA15.1|H_LUCA16.1		obo:civic.gid#gene	
2317	GNAQ		CMAL|CMC1|G-ALPHA-q|GAQ|SWS		obo:civic.gid#gene	
2319	GNAS		AHO|C20orf45|GNAS1|GPSA|GSA|GSP|NESP|PITA3|POH|SCG6|SgVI		obo:civic.gid#gene	
24	FLT3	FLT3 is an important cytokine receptor involved in normal hematopoiesis. Mutations in this gene are common in acute myeloid leukemia (AML) and screening for mutations in this gene has been recommended by the World Health Organization in patients with AML, particularly in cases of cytogenetically normal AML (CN-AML). FLT3 mutations commonly co-occur with mutations such as NPM1 that are associated with CN-AML and likely modulate prognostic impact. While FLT3-ITD mutations have been associated with poorer prognosis in AML, the prognostic impact of FLT3-TKD mutations are still up for debate.	CD135|FLK-2|FLK2|STK1		obo:civic.gid#gene	
24374	EML6				obo:civic.gid#gene	
2438	ARHGAP35		GRF-1|GRLF1|P190-A|P190A|p190ARhoGAP|p190RhoGAP		obo:civic.gid#gene	
2473	GSTP1		DFN7|FAEES3|GST3|GSTP|HEL-S-22|PI		obo:civic.gid#gene	
2478	MSH6		GTBP|GTMBP|HNPCC5|HSAP|LYNCH5|MMRCS3|MSH-6|p160		obo:civic.gid#gene	
24929	MIR21		MIRN21|hsa-mir-21|miR-21|miRNA21		obo:civic.gid#gene	
24938	MIR218-1		MIRN218-1|mir-218-1		obo:civic.gid#gene	
25	GATA2	GATA2 is a transcription factor involved in stem cell maintenance with key roles in hematopoietic development. GATA2 mutations are associated with a variety of inherited and acquired immune disorders including myelodysplastic syndrome and acute myeloid leukemia. In addition to a role in hematopoiesis, the maintenance GATA2 expression has been implicated as a requirement in KRAS-driven non-small cell lung cancer. Preclinical models have indicated therapeutic benefit from targeting GATA2-mediated pathways in the context of KRAS-driven NSCLC.	DCML|IMD21|MONOMAC|NFE1B		obo:civic.gid#gene	
2526	H1-2		H1.2|H1C|H1F2|H1s-1|HIST1H1C		obo:civic.gid#gene	
2527	H1-3		H1.3|H1D|H1F3|H1s-2|HIST1H1D		obo:civic.gid#gene	
2529	H1-5		H1|H1.5|H1B|H1F5|H1s-3|HIST1H1B		obo:civic.gid#gene	
2535	H2BC5		H2B.1B|H2B/a|H2B/b|H2B/g|H2B/h|H2B/k|H2B/l|H2BFA|H2BFB|H2BFG|H2BFH|H2BFK|H2BFL|HIRIP2|HIST1H2BC|HIST1H2BD|HIST1H2BE|HIST1H2BF|HIST1H2BG|HIST1H2BI|dJ221C16.6		obo:civic.gid#gene	
2537	H3-3A		BRYLIB1|H3-3B|H3.3A|H3F3|H3F3A		obo:civic.gid#gene	
2538	H3-3B		BRYLIB2|H3-3A|H3.3B|H3F3B		obo:civic.gid#gene	
254	AKT2		HIHGHH|PKBB|PKBBETA|PRKBB|RAC-BETA		obo:civic.gid#gene	
2556	HBB		CD113t-C|ECYT6|beta-globin		obo:civic.gid#gene	
2578	HDAC2		HD2|KDAC2|RPD3|YAF1		obo:civic.gid#gene	
259	ALCAM		CD166|MEMD		obo:civic.gid#gene	
2591	HGF		DFNB39|F-TCF|HGFB|HPTA|SF		obo:civic.gid#gene	
2593	NRG1		ARIA|GGF|GGF2|HGL|HRG|HRG1|HRGA|MST131|MSTP131|NDF|NRG1-IT2|SMDF		obo:civic.gid#gene	
2596	HIF1A		HIF-1-alpha|HIF-1A|HIF-1alpha|HIF1|HIF1-ALPHA|MOP1|PASD8|bHLHe78		obo:civic.gid#gene	
26	IDH1	IDH1 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. The implications of mutations in this gene vary greatly by cancer type. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 mutations have been associated with worse outcome, shorter overall survival, and normal karyotype. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Unlike the association with cytogenetically normal AML, in glioblastoma, IDH1 mutations have been associated with specific cytogenetic abnormalities, 1p and 19q deletions.	HEL-216|HEL-S-26|IDCD|IDH|IDP|IDPC|PICD		obo:civic.gid#gene	
2606	HLA-A		HLAA		obo:civic.gid#gene	
2607	HLA-B		AS|B-4901|HLAB		obo:civic.gid#gene	
2608	HLA-C		D6S204|HLA-JY3|HLAC|HLC-C|MHC|PSORS1		obo:civic.gid#gene	
2622	HLA-DRA		HLA-DRA1		obo:civic.gid#gene	
2657	HMOX1		HMOX1D|HO-1|HSP32|bK286B10		obo:civic.gid#gene	
26599	ECSCR		ARIA|ECSM2		obo:civic.gid#gene	
2677	HNRNPH1		HNRPH|HNRPH1|NEDCDS|hnRNPH		obo:civic.gid#gene	
2682	HNRNPU		DEE54|EIEE54|GRIP120|HNRNPU-AS1|HNRPU|SAF-A|SAFA|U21.1|hnRNP U|pp120		obo:civic.gid#gene	
27	IDH2	IDH2 mutations have been observed in a number of cancer types, including sarcomas, hematologic malignancies, colon cancer and brain cancer. Mutations in the two isocitrate dehydrogenase enzymes involved in cytoplasmic (IDH1) and mitochondrial (IDH2) conversion of alpha-ketoglutarate to D-2-hydroxyglutarate have been described as mutually exclusive in many of these cancer types. The most frequent mutations involve R132 (IDH1) and R172 (IDH2) involve the active site and result in neomorphic enzyme activity. Although IDH2 (R172) mutations are associated with poorer overall prognosis in AML patients, its utility as a prognostic marker in MDS is still under debate. Additionally, IDH2 (R140) has been associated with improved overall survival in AML. IDH2 mutations have been associated with improved prognosis in gliomas.	D2HGA2|ICD-M|IDH|IDH-2|IDHM|IDP|IDPM|mNADP-IDH		obo:civic.gid#gene	
2715	HOXC10		HOX3I		obo:civic.gid#gene	
2723	HOXD8		HOX4|HOX4E|HOX5.4		obo:civic.gid#gene	
2747	HRAS		C-BAS/HAS|C-H-RAS|C-HA-RAS1|CTLO|H-RASIDX|HAMSV|HRAS1|RASH1|p21ras		obo:civic.gid#gene	
2778	HSPA5		BIP|GRP78|HEL-S-89n		obo:civic.gid#gene	
2784	HSPB1		CMT2F|HEL-S-102|HMN2B|HMND3|HS.76067|HSP27|HSP28|Hsp25|SRP27		obo:civic.gid#gene	
28	JAK2	JAK2 is a kinase that is misregulated or mutated in a number of myeloproliferative diseases and cancers. The mutation V617F is the most clinically relevant variant, and is seen in around half of myeloproliferative disorders. The variant is a known activating mutation, and activated JAK2 is sufficient to drive myeloproliferative disorders in mouse models. V617F, while most recurrent, is not the only mechanism by which JAK2 can be activated in patients. JAK2 is now one of the first diagnostic markers tested upon diagnosis with a myeloproliferative disorder.	JTK10		obo:civic.gid#gene	
2822	TNC		150-225|DFNA56|GMEM|GP|HXB|JI|TN|TN-C		obo:civic.gid#gene	
2836	IRF8		H-ICSBP|ICSBP|ICSBP1|IMD32A|IMD32B|IRF-8		obo:civic.gid#gene	
2840	ID3		HEIR-1|bHLHb25		obo:civic.gid#gene	
2888	IFNGR1		CD119|IFNGR|IMD27A|IMD27B		obo:civic.gid#gene	
2899	IGF1R		CD221|IGFIR|IGFR|JTK13		obo:civic.gid#gene	
29	KIT	c-KIT activation has been shown to have oncogenic activity in gastrointestinal stromal tumors (GISTs), melanomas, lung cancer, and other tumor types. The targeted therapeutics nilotinib and sunitinib have shown efficacy in treating KIT overactive patients, and are in late-stage trials in melanoma and GIST. KIT overactivity can be the result of many genomic events from genomic amplification to overexpression to missense mutations. Missense mutations have been shown to be key players in mediating clinical response and acquired resistance in patients being treated with these targeted therapeutics.	C-Kit|CD117|MASTC|PBT|SCFR		obo:civic.gid#gene	
2967	IL4R		CD124|IL-4RA|IL4RA		obo:civic.gid#gene	
2970	IL6		BSF-2|BSF2|CDF|HGF|HSF|IFN-beta-2|IFNB2|IL-6		obo:civic.gid#gene	
2975	IL7R		CD127|CDW127|IL-7R-alpha|IL-7Ralpha|IL7RA|IL7Ralpha|ILRA|IMD104|lnc-IL7R|sIL-7R		obo:civic.gid#gene	
3	ARAF	ARAF has recently become increasingly considered for its oncogenic potential. Its potential as a target for informing clinical action was demonstrated by a single case of advanced lung adenocarcinoma harboring an S214C mutation that, when treated with sorafenib, acheived near-complete clinical remission. This finding has brought new focus on ARAF as a marker that should be assayed for in cancer treatment.	A-RAF|ARAF1|PKS2|RAFA1		obo:civic.gid#gene	
30	KRAS	Mutations in the RAS family of proteins are frequently observed across cancer types. The amino acid positions that account for the overwhelming majority of these mutations are G12, G13 and Q61. The different protein isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, attempts to target these RAS mutants with inhibitors have not been successful, and has not yet become common practice in the clinic. The prognostic implications for KRAS mutations vary between cancer types, but have been shown to be associated with poor outcome in colorectal cancer, non-small cell lung cancer, and others.	'C-K-RAS|C-K-RAS|CFC2|K-RAS2A|K-RAS2B|K-RAS4A|K-RAS4B|K-Ras|K-Ras 2|KI-RAS|KRAS1|KRAS2|NS|NS3|OES|RALD|RASK2|c-Ki-ras|c-Ki-ras2		obo:civic.gid#gene	
3017	CXCL10		C7|IFI10|INP10|IP-10|SCYB10|crg-2|gIP-10|mob-1		obo:civic.gid#gene	
3043	IRF4		LSIRF|MUM1|NF-EM5|SHEP8		obo:civic.gid#gene	
3083	ITPKB		IP3-3KB|IP3K|IP3K-B|IP3KB|PIG37		obo:civic.gid#gene	
3090	JAK1		AIIDE|JAK1A|JAK1B|JTK3		obo:civic.gid#gene	
3091	JAK3		JAK-3|JAK3_HUMAN|JAKL|L-JAK|LJAK		obo:civic.gid#gene	
3094	JUN		AP-1|AP1|c-Jun|cJUN|p39		obo:civic.gid#gene	
31	MAP2K1	MAP2K1 is a dual-specificity kinase known for it's involvement in the ERK pathway by activation of ERK1 and ERK2. MAP2K1 activating mutations have been observed in a number of cancers including ovarian, melanoma and lung. These activating mutations are generally found in the N-terminal negative regulatory region or the ATP-binding region of the N-terminal lobe. Inhibitors of MEK genes have been shown to inhibit tumor growth in these cases.	CFC3|MAPKK1|MEK1|MEL|MKK1|PRKMK1		obo:civic.gid#gene	
3153	KDR		CD309|FLK1|VEGFR|VEGFR2		obo:civic.gid#gene	
32	MEF2D				obo:civic.gid#gene	
32083	KLLN		CWS4|KILLIN		obo:civic.gid#gene	
3215	KRT18		CK-18|CYK18|K18		obo:civic.gid#gene	
3236	LAG3		CD223		obo:civic.gid#gene	
3255	STMN1		C1orf215|LAP18|Lag|OP18|PP17|PP19|PR22|SMN		obo:civic.gid#gene	
3274	LEPR		CD295|LEP-R|LEPRD|OB-R|OBR		obo:civic.gid#gene	
33	CSF1R		BANDDOS|C-FMS|CD115|CSF-1R|CSFR|FIM2|FMS|GPSC|HDLS|HDLS1|M-CSF-R		obo:civic.gid#gene	
3342	LTB		TNFC|TNFSF3|TNLG1C|p33		obo:civic.gid#gene	
3359	LYN		JTK8|SAIDV|p53Lyn|p56Lyn		obo:civic.gid#gene	
3362	TACSTD2		EGP-1|EGP1|GA733-1|GA7331|GP50|M1S1|TROP2		obo:civic.gid#gene	
3364	EPCAM		Ber-Ep4|BerEp4|DIAR5|EGP-2|EGP314|EGP40|ESA|HNPCC8|KS1/4|KSA|LYNCH8|M4S1|MIC18|MK-1|MOC-31|TACSTD1|TROP1		obo:civic.gid#gene	
3375	SMAD2		CHTD8|JV18|JV18-1|LDS6|MADH2|MADR2|hMAD-2|hSMAD2		obo:civic.gid#gene	
3376	SMAD3		HSPC193|HsT17436|JV15-2|LDS1C|LDS3|MADH3|hMAD-3|hSMAD3|mad3		obo:civic.gid#gene	
33873	MEF2B		RSRFR2		obo:civic.gid#gene	
3389	MAGEA4		CT1.4|MAGE-41|MAGE-X2|MAGE4|MAGE4A|MAGE4B		obo:civic.gid#gene	
34	MGMT				obo:civic.gid#gene	
3448	MCL1		BCL2L3|EAT|MCL1-ES|MCL1L|MCL1S|Mcl-1|TM|bcl2-L-3|mcl1/EAT		obo:civic.gid#gene	
3465	MDM2		ACTFS|HDMX|LSKB|hdm2		obo:civic.gid#gene	
3466	MDM4		BMFS6|HDMX|MDMX|MRP1		obo:civic.gid#gene	
3475	MEF2C		C5DELq14.3|DEL5q14.3|NEDHSIL		obo:civic.gid#gene	
3480	MAP3K1		MAPKKK1|MEKK|MEKK 1|MEKK1|SRXY6		obo:civic.gid#gene	
3485	MEN1		MEAI|SCG2		obo:civic.gid#gene	
35	NPM1	AML with mutated NPM1 is a provisional entity in the WHO classification of AML and is recommended to be tested in patients with cytogenetically normal AML (CN-AML). FLT3 mutations should be evaluated concurrently as they have prognostic consequences. NPM1 mutations are concentrated in exon 12, most frequently W288fs which results in cytoplasmic sequestration of the protein. Exon 12 NPM1 mutations in the absence of FLT3-ITD are associated with good prognostic outcomes. Mice expressing the Npm1-W288fs mutation develop myeloproliferative neoplasms but not overt leukemia, indicating it may require additional mutations to promote leukemic development.	B23|NPM		obo:civic.gid#gene	
3512	CIITA		C2TA|CIITAIV|MHC2D1|MHC2TA|NLRA		obo:civic.gid#gene	
3527	MITF		CMM8|COMMAD|MI|MITF-A|WS2|WS2A|bHLHe32		obo:civic.gid#gene	
3529	MKI67		KIA|MIB-|MIB-1|PPP1R105		obo:civic.gid#gene	
353	BIRC3		AIP1|API2|CIAP2|HAIP1|HIAP1|IAP-1|MALT2|MIHC|RNF49|c-IAP2		obo:civic.gid#gene	
3532	MLH1	MLH1 is a tumor suppressor gene involved in DNA mismatch repair. Germline mutations in this gene are known to cause Lynch syndrome. The most common malignancies in Lynch syndrome are colorectal and endometrial carcinomas. In addition to germline mutations, somatic mutations in this gene have been described in colorectal and endometrial cancers.	COCA2|FCC2|HNPCC|HNPCC2|LYNCH2|MLH-1|MMRCS1|hMLH1		obo:civic.gid#gene	
3537	KMT2A		ALL-1|ALL1|CXXC7|GAS7|HRX|HTRX|HTRX1|MLL|MLL1|MLL1A|TRX1|WDSTS		obo:civic.gid#gene	
3549	MMP2		CLG4|CLG4A|MMP-2|MMP-II|MONA|TBE-1		obo:civic.gid#gene	
355	BIRC5		API4|EPR-1		obo:civic.gid#gene	
3553	MMP9		CLG4B|GELB|MANDP2|MMP-9		obo:civic.gid#gene	
3564	MN1		CEBALID|MGCR|MGCR1|MGCR1-PEN|dJ353E16.2		obo:civic.gid#gene	
3577	MPL		C-MPL|CD110|MPLV|THCYT2|THPOR|TPOR		obo:civic.gid#gene	
3586	MRE11		ATLD|HNGS1|MRE11A|MRE11B		obo:civic.gid#gene	
36	NRAS	Mutations in the RAS family of proteins have frequently been observed across cancer types. The amino acid positions G12, G13 and Q61 account for the overwhelming majority of these mutations. The isoforms, despite their raw similarity, also behave very differently when expressed in non-native tissue types, likely due to differences in the C-terminal hyper-variable regions. Mis-regulation of isoform expression has been shown to be a driving event in cancer, as well as missense mutations at the three hotspots previously mentioned. While highly recurrent in cancer, targeting these RAS mutants has also been very elusive, and has not yet become common practice in the clinic.	ALPS4|CMNS|KRAS|N-ras|NCMS|NRAS1|NS6		obo:civic.gid#gene	
3628	MSH2		COCA1|FCC1|HNPCC|HNPCC1|LCFS2|LYNCH1|MMRCS2|MSH-2|hMSH2		obo:civic.gid#gene	
3629	MSH3		DUP|FAP4|MRP1		obo:civic.gid#gene	
3659	MTAP		BDMF|DMSFH|DMSMFH|HEL-249|LGMBF|MSAP|c86fus		obo:civic.gid#gene	
3672	MTHFR				obo:civic.gid#gene	
37	PIK3CA	PIK3CA is the most recurrently mutated gene in breast cancer, and has been found to important in a number of cancer types. An integral part of the PI3K pathway, PIK3CA has long been described as an oncogene, with two main hotspots for activating mutations, the 542/545 region of the helical domain, and the 1047 region of the kinase domain. PIK3CA, and its interaction with the AKT and mTOR pathways, is the subject of an immense amount of research and development, and PI3K inhibition has seen some limited success in recent clinical trials. While monotherapies seem to be limited in their potential, there is a recent interest in pursuing PI3K inhibition as part of a combination therapy regiment with inhibition partners including TKI's, MEK inhibitors, PARP inhibitors, and in breast cancer, aromatase inhibitors.	CCM4|CLAPO|CLOVE|CWS5|HMH|MCAP|MCM|MCMTC|PI3K|PI3K-alpha|p110-alpha		obo:civic.gid#gene	
3730	MYB		Cmyb|c-myb|c-myb_CDS|efg		obo:civic.gid#gene	
3731	MYBL1		A-MYB|AMYB		obo:civic.gid#gene	
3737	MYC		MRTL|MYCC|bHLHe39|c-Myc		obo:civic.gid#gene	
3738	MYCL		L-Myc|LMYC|MYCL1|bHLHe38		obo:civic.gid#gene	
3741	MYCN		FGLDS1|MODED|MPAPA|MYCNsORF|MYCNsPEP|N-myc|NMYC|ODED|bHLHe37		obo:civic.gid#gene	
3742	MYD88		IMD68|MYD88D|WM1		obo:civic.gid#gene	
375	FAS		ALPS1A|APO-1|APT1|CD95|FAS1|FASTM|TNFRSF6		obo:civic.gid#gene	
3777	MYOD1		CMYO17|CMYP17|MYF3|MYOD|MYODRIF|PUM|bHLHc1		obo:civic.gid#gene	
38	PDGFRA	Commonly mutated in GI tract tumors, PDGFR family genes (mutually exclusive to KIT mutations) are a hallmark of gastrointestinal stromal tumors. Gene fusions involving the PDGFRA kinase domain are highly correlated with eosinophilia, and the WHO classifies myeloid and lymphoid neoplasms with these characteristics as a distinct disorder. Mutations in the 842 region of PDGFRA have been often found to confer resistance to the tyrosine kinase inhibitor, imatinib.	CD140A|PDGFR-2|PDGFR2		obo:civic.gid#gene	
3801	NBN		AT-V1|AT-V2|ATV|NBS|NBS1|P95|hNbs1		obo:civic.gid#gene	
3852	NEDD9		CAS-L|CAS2|CASL|CASS2|HEF1		obo:civic.gid#gene	
3867	NF1		NFNS|VRNF|WSS		obo:civic.gid#gene	
3870	NF2		ACN|BANF|SCH|SWNV|merlin-1		obo:civic.gid#gene	
3878	NFE2L2		HEBP1|IMDDHH|NRF2|Nrf-2		obo:civic.gid#gene	
3885	NFKBIA		EDAID2|IKBA|MAD-3|NFKBI		obo:civic.gid#gene	
3887	NFKBIE		IKBE		obo:civic.gid#gene	
389	AREG		AR|AREGB|CRDGF|SDGF		obo:civic.gid#gene	
39	PML	The PML-RARA fusion is the result of a recurrent, balanced translocation between chromosomes 15 and 17, denoted as t(15;17)(q22;q12), and a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA (all-trans retinoic acid) in APL patients harboring the PML-RARA fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising. However, newly discovered mutations in the B2 domain of PML have started to show conferred resistance to ATRA in these patients.	MYL|PP8675|RNF71|TRIM19		obo:civic.gid#gene	
3935	NOTCH2		AGS2|HJCYS|hN2		obo:civic.gid#gene	
3936	NOTCH3		CADASIL|CADASIL1|CASIL|IMF2|LMNS		obo:civic.gid#gene	
3976	NT5E		CALJA|CD73|E5NT|NT|NT5|NTE|eN|eNT		obo:civic.gid#gene	
3983	NTRK1		MTC|TRK|TRK1|TRKA|Trk-A|p140-TrkA		obo:civic.gid#gene	
3984	NTRK2		DEE58|EIEE58|GP145-TrkB|OBHD|TRKB|trk-B		obo:civic.gid#gene	
3985	NTRK3		GP145-TrkC|TRKC|gp145(trkC)		obo:civic.gid#gene	
399	RHOA		ARH12|ARHA|EDFAOB|RHO12|RHOH12		obo:civic.gid#gene	
4	ABL1	ABL1 is most relevant to cancer in its role in the BCR-ABL fusion protein that has become a signature of chronic myeloid leukemia (CML). Cells harboring this fusion have shown sensitivity to imatinib, greatly improving the prognostic outlook of the disease. However, additional mutations in ABL1 have been shown to confer resistance to imatinib. In these resistance cases, second-generation tyrosine kinase inhibitors such as dasatinib and nilotinib have exhibited some efficacy and are currently undergoing clinical trials for treating acquired resistance in CML.	ABL|BCR-ABL|CHDSKM|JTK7|bcr/abl|c-ABL|c-ABL1|p150|v-abl		obo:civic.gid#gene	
4046	ORC1		HSORC1|ORC1L|PARC1		obo:civic.gid#gene	
41	PTEN	PTEN is a multi-functional tumor suppressor that is very commonly lost in human cancer. Observed in prostate cancer, glioblastoma, endometrial, lung and breast cancer to varying degrees. Up to 70% of prostate cancer patients have been observed to have loss of expression of the gene. It is a part of the PI3K/AKT/mTOR pathway and mTOR inhibitors have been relatively ineffective in treating patients with PTEN loss. New appoaches using microRNAs are currently being investigated.	10q23del|BZS|CWS1|DEC|GLM2|MHAM|MMAC1|PTEN1|PTENbeta|PTENgama|TEP1		obo:civic.gid#gene	
4103	PRKN		AR-JP|LPRS2|PARK2|PDJ		obo:civic.gid#gene	
4111	PAX5		ALL3|BSAP|PAX-5		obo:civic.gid#gene	
4123	PCBP1		HEL-S-85|HNRPE1|HNRPX|hnRNP-E1|hnRNP-X		obo:civic.gid#gene	
4137	PCNA		ATLD2		obo:civic.gid#gene	
41522	PRNCR1		CARLo-3|PCAT8		obo:civic.gid#gene	
4173	PDGFB		IBGC5|PDGF-2|PDGF2|SIS|SSV|c-sis		obo:civic.gid#gene	
4176	PDGFRB		CD140B|IBGC4|IMF1|JTK12|KOGS|PDGFR|PDGFR-1|PDGFR1|PENTT		obo:civic.gid#gene	
42	RET	RET mutations and the RET fusion RET-PTC lead to activation of this tyrosine kinase receptor and are associated with thyroid cancers. RET point mutations are the most common mutations identified in medullary thyroid cancer (MTC) with germline and somatic mutations in RET associated with hereditary and sporadic forms, respectively. The most common somatic form mutation is M918T (exon 16) and a variety of other mutations effecting exons 10, 11 and 15 have been described. The prognostic significance of these mutations have been hotly debated in the field, however, data suggests that some RET mutation may confer drug resistance. Highly selective and well-tolerated RET inhibitors, selpercatinib (LOXO-292) and pralsetinib (BLU-667), have been FDA approved recently for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer.	CDHF12|CDHR16|HSCR1|MEN2A|MEN2B|MTC1|PTC|RET-ELE1		obo:civic.gid#gene	
4244	ABCB1		ABC20|CD243|CLCS|GP170|MDR1|P-GP|PGY1|p-170		obo:civic.gid#gene	
4285	PIK3CB		P110BETA|PI3K|PI3KBETA|PIK3C1		obo:civic.gid#gene	
4286	PIM1		PIM		obo:civic.gid#gene	
4289	PIK3R1		AGM7|GRB1|IMD36|p85|p85-ALPHA|p85alpha		obo:civic.gid#gene	
4290	PIK3R2		MPPH|MPPH1|P85B|p85|p85-BETA|p85beta		obo:civic.gid#gene	
43	RUNX1	RUNX1 is a transcription factor that forms a complex with the cofactor CBFB. This complex provides stability to the RUNX1 protein which is involved in the generation of hematopoietic stem cells and for their differentiation into myeloid and lymphoid lines. Loss of RUNX1 function has been shown to impair differentiation between myeloid and lymphoid lines often resulting in the development of leukemia.	AML1|AML1-EVI-1|AMLCR1|CBF2alpha|CBFA2|EVI-1|PEBP2aB|PEBP2alpha		obo:civic.gid#gene	
4326	PLCG1		IDAA|NCKAP3|PLC-II|PLC1|PLC148|PLCgamma1		obo:civic.gid#gene	
4327	PLCG2		APLAID|FCAS3|PLC-IV|PLC-gamma-2		obo:civic.gid#gene	
4337	PLK1		PLK|STPK13		obo:civic.gid#gene	
436	ASCL1		ASH1|HASH1|MASH1|bHLHa46		obo:civic.gid#gene	
4371	PMS2		HNPCC4|LYNCH4|MLH4|MMRCS4|PMS-2|PMS2CL|PMSL2		obo:civic.gid#gene	
4384	POLD1		CDC2|CRCS10|IMD120|MDPL|POLD		obo:civic.gid#gene	
4386	POLE		CRCS12|FILS|IMAGEI|POLE1		obo:civic.gid#gene	
44	SF3B1	SF3B1 mutations have been described in several myeloid malignancies, predominantly myelodysplastic syndromes (MDS), as well as other hematologic malignancies, breast cancer, and uveal melanoma (UM). SF3B1 is one of several genes involved in RNA splicing that has been identified as recurrently mutated in MDS and other malignanices. The mutations affecting SF3B1 are typically heterozygous, point mutations suspected to be functionally deleterious with R625 and K700E described as a major mutation hotspots. MDS patients with SF3B1 mutations have been reported to have better overall and event-free survival than their wildtype counterparts. Additionally, these mutations are highly associated with subtypes of MDS characterized by ringed sideroblasts (refractory anemia with ringed sideroblasts and refractory cytopenia with multilineage dysplasia and ring sideroblasts). In UM patients, SF3B1 mutations have been reported to be associated with chromosome 3 disomy, which defines a subgroup with low risk of metastasis.	Hsh155|MDS|PRP10|PRPF10|SAP155|SF3b155		obo:civic.gid#gene	
4409	POU2AF1		BOB1|OBF-1|OBF1|OCAB		obo:civic.gid#gene	
4411	POU2F2		OCT2|OTF2|Oct-2		obo:civic.gid#gene	
4419	POU5F1		OCT3|OCT4|OTF-3|OTF3|OTF4|Oct-3|Oct-4|Oct3/4		obo:civic.gid#gene	
446	ASNS		ASNSD|TS11		obo:civic.gid#gene	
4463	PPP2R1A		HJS2|MRD36|PP2A-Aalpha|PP2AA|PP2AAALPHA|PR65A		obo:civic.gid#gene	
4465	PPP2R2A		B55A|B55ALPHA|PR52A|PR55A|PR55alpha		obo:civic.gid#gene	
45	TP53	TP53 mutations are universal across cancer types. The loss of a tumor suppressor is most often through large deleterious events, such as frameshift mutations, or premature stop codons. In TP53 however, many of the observed mutations in cancer are found to be single nucleotide missense variants. These variants are broadly distributed throughout the gene, but with the majority localizing in the DNA binding domain. There is no single hotspot in the DNA binding domain, but a majority of mutations occur in amino acid positions 175, 245, 248, 273, and 282 (NM_000546) (Olivier et al., 2010). To fulfill its proper biological function four TP53 polypeptides must form a tetramer which functions as a transcription factor, therefore even if one out of four polypeptides has inactivating mutation it may lead to dominant negative phenotype of variable degree. While a large proportion of cancer genomics research is focused on somatic variants, TP53 is also of note in the germline. Germline TP53 mutations are the hallmark of Li-Fraumeni syndrome, and many (both germline and somatic) variants have been found to have a prognostic impact on patient outcomes. The significance of many polymorphisms for susceptibility and prognosis of disease is still very much up for debate.	BCC7|BMFS5|LFS1|P53|TRP53		obo:civic.gid#gene	
450	ASS1		ASS|CTLN1		obo:civic.gid#gene	
4503	PRKAA2		AMPK|AMPK2|AMPKa2|PRKAA		obo:civic.gid#gene	
4511	PRKAR1A		ACRDYS1|ADOHR|CAR|CNC|CNC1|PKR1|PPNAD1|PRKAR1|Prkar1alpha|TSE1		obo:civic.gid#gene	
4517	PRKCB		PKC-beta|PKCB|PKCI(2)|PKCbeta|PRKCB1|PRKCB2		obo:civic.gid#gene	
4529	PRKDC		DNA-PKC|DNA-PKcs|DNAPK|DNAPKc|DNPK1|HYRC|HYRC1|IMD26|XRCC7|p350		obo:civic.gid#gene	
4532	MAPK1		ERK|ERK-2|ERK2|ERT1|MAPK2|NS13|P42MAPK|PRKM1|PRKM2|p38|p40|p41|p41mapk|p42-MAPK		obo:civic.gid#gene	
4542	MAP2K2		CFC4|MAPKK2|MEK2|MKK2|PRKMK2		obo:civic.gid#gene	
4546	MAP2K7		JNKK2|MAPKK7|MEK|MEK 7|MKK7|PRKMK7|SAPKK-4|SAPKK4		obo:civic.gid#gene	
4566	PRPS1		ARTS|CMTX5|DFN2|DFNX1|PPRibP|PRS-I|PRSI		obo:civic.gid#gene	
46	TSC1		LAM|TSC		obo:civic.gid#gene	
4616	PSMB8		ALDD|D6S216|D6S216E|JMP|LMP7|NKJO|PRAAS1|PSMB5i|RING10		obo:civic.gid#gene	
4630	PSMD4		AF|AF-1|ASF|MCB1|Rpn10|S5A|pUB-R5		obo:civic.gid#gene	
4645	PTCH1		BCNS|BCNS1|NBCCS|PTC|PTC1|PTCH		obo:civic.gid#gene	
4659	PTGS2		COX-2|COX2|GRIPGHS|PGG/HS|PGHS-2|PHS-2|hCox-2		obo:civic.gid#gene	
4682	PTPN6		HCP|HCPH|HPTP1C|PTP-1C|SH-PTP1|SHP-1|SHP-1L|SHP1		obo:civic.gid#gene	
4685	PTPN11		BPTP3|CFC|JMML|METCDS|NS1|PTP-1D|PTP2C|SH-PTP2|SH-PTP3|SHP2		obo:civic.gid#gene	
4686	PTPN12		PTP-PEST|PTPG1		obo:civic.gid#gene	
4690	PTPRB		HPTP-BETA|HPTPB|PTPB|R-PTP-BETA|VEPTP		obo:civic.gid#gene	
4692	PTPRD		HPTP|HPTPD|HPTPDELTA|PTPD|R-PTP-delta|RPTPDELTA		obo:civic.gid#gene	
4695	PTPRF		BNAH2|LAR		obo:civic.gid#gene	
47	TSC2		LAM|PPP1R160|TSC4		obo:civic.gid#gene	
4753	RAC1	The RAC1 P29S mutation is the third most common protein-coding hotspot mutation in melanomas, ocurring in 4-9%. A preclinical study has shown that this mutation confers resistance to BRAF inhibition in-vitro.	MIG5|MRD48|Rac-1|TC-25|p21-Rac1		obo:civic.gid#gene	
4760	RAD23B		HHR23B|HR23B|P58		obo:civic.gid#gene	
4762	RAD51C		BROVCA3|FANCO|R51H3|RAD51L2		obo:civic.gid#gene	
4763	RAD51B		R51H2|RAD51L1|REC2		obo:civic.gid#gene	
4765	RAD51D		BROVCA4|R51H3|RAD51L3|TRAD		obo:civic.gid#gene	
4767	RAF1		CMD1NN|CRAF|NS5|Raf-1|c-Raf		obo:civic.gid#gene	
4791	RASA1		CM-AVM|CMAVM|CMAVM1|GAP|PKWS|RASA|RASGAP|p120|p120GAP|p120RASGAP		obo:civic.gid#gene	
4795	RB1		OSRC|PPP1R130|RB|p105-Rb|p110-RB1|pRb|pp110		obo:civic.gid#gene	
48	U2AF1	U2AF1 is one of several spliceosome complex genes frequently mutated in a variety of hematologic malignancies, particularly de novo myelodysplastic syndromes (MDS), as well as solid tumors such as lung and pancreatic cancers. Two hotspot mutations (S34 and Q157) occur within the two zinc-finger domains of the U2AF1 protein. These mutations have been associated with altered splicing patterns in vitro and in vivo. U2AF1 mutations in MDS have been associated with an increased risk of transformation to secondary acute myeloid leukemia, however, the impact of these mutations on overall survival has been an area of debate.	FP793|RN|RNU2AF1|U2AF35|U2AFBP		obo:civic.gid#gene	
4868	RHEB		RHEB2		obo:civic.gid#gene	
4875	RIT1		NS8|RIBB|RIT|ROC1		obo:civic.gid#gene	
49	WT1	WT1 is a tumor suppressor gene associated with the development of Wilms' Tumor, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance.	AWT1|GUD|NPHS4|WAGR|WIT-2|WT-1|WT33		obo:civic.gid#gene	
4941	ROS1	ROS1 is a receptor tyrosine kinase that is frequently involved in genetic rearrangement in a variety of human cancers (e.g. NSCLC, gastric cancer, ovarian cancer, cholangiocarcinoma, colorectal cancer, angiosarcoma...). The resulting fusion protein harbors the constitutively active ROS1 kinase domain and drives cellular proliferation (Davies et. al.). In NSCLC about 1% harbor a ROS1 rearrangement. These patients are predominantely female and have a lower T-stage (Warth et. al.). Treatment with crizotinib leads to a reported objective response rate of appr. 70% and a median duration of response of 18 months (Shaw et. al.). Resistance mechanisms to crizotinib have been described and involve mutations in the kinase domain. More selective inhibitors of ROS1 might overcome this resistance (Davare et. al.).	MCF3|ROS|c-ros-1		obo:civic.gid#gene	
5	BRAF	BRAF mutations are found to be recurrent in many cancer types. Of these, the mutation of valine 600 to glutamic acid (V600E) is the most prevalent. V600E has been determined to be an activating mutation, and cells that harbor it, along with other V600 mutations are sensitive to the BRAF inhibitor dabrafenib. It is also common to use MEK inhibition as a substitute for BRAF inhibitors, and the MEK inhibitor trametinib has seen some success in BRAF mutant melanomas. BRAF mutations have also been correlated with poor prognosis in many cancer types, although there is at least one study that questions this conclusion in papillary thyroid cancer. Oncogenic BRAF mutations are divided into three categories that determine their sensitivity to inhibitors. Class 1 BRAF mutations (V600) are RAS-independent, signal as monomers and are sensitive to current RAF monomer inhibitors. Class 2 BRAF mutations (K601E, K601N, K601T, L597Q, L597V, G469A, G469V, G469R, G464V, G464E, and fusions) are RAS-independent, signaling as constitutive dimers and are resistant to vemurafenib. Such mutants may be sensitive to novel RAF dimer inhibitors or MEK inhibitors. Class 3 BRAF mutations (D287H, V459L, G466V, G466E, G466A, S467L, G469E, N581S, N581I, D594N, D594G, D594A, D594H, F595L, G596D, and G596R) with low or absent kinase activity are RAS-dependent and they activate ERK by increasing their binding to activated RAS and wild-type CRAF. Class 3 BRAF mutations coexist with mutations in RAS or NF1 in melanoma may be treated with MEK inhibitors. In epithelial tumors such as CRC or NSCLC may be effectively treated with combinations that include inhibitors of receptor tyrosine kinase.	B-RAF1|B-raf|BRAF-1|BRAF1|NS7|RAFB1		obo:civic.gid#gene	
50	NOTCH1	NOTCH1 is one of four known genes encoding the NOTCH family of proteins, a group of receptors involved in the Notch signaling pathway. NOTCH proteins are characterized by N-terminal EGF-like repeats followed by LNR domains which form a complex with ligands to prevent signaling. The Notch signaling pathway is involved in processes related to cell fate specification, differentiation, proliferation, and survival. Activation of Notch has been shown to be correlative with mammary tumorgenesis in mice and increased expression of Notch receptors has been observed in a variety of cancer types including cervical, colon, head and neck, lung, renal, pancreatic, leukemia, and breast cancer. A number of treatment modalities have been explored related to Notch inhibition especially in breast cancer with mixed results.	AOS5|AOVD1|TAN1|hN1		obo:civic.gid#gene	
5013	RPS6		S6|eS6		obo:civic.gid#gene	
5051	RRM1		PEOB6|R1|RIR1|RR1		obo:civic.gid#gene	
5052	RRM2		C2orf48|R2|RR2|RR2M		obo:civic.gid#gene	
5087	S100B		NEF|S100|S100-B|S100beta		obo:civic.gid#gene	
51	DDR2		MIG20a|NTRKR3|TKT|TYRO10|WRCN		obo:civic.gid#gene	
5112	ATXN7		ADCAII|OPCA3|SCA7|SGF73		obo:civic.gid#gene	
5128	SCN8A		BFIS5|CERIII|CIAT|DEE13|EIEE13|MED|MYOCL2|NaCh6|Nav1.6|PN4		obo:civic.gid#gene	
5167	CX3CL1		ABCD-3|C3Xkine|CXC3|CXC3C|NTN|NTT|SCYD1|fractalkine|neurotactin		obo:civic.gid#gene	
5176	SDHA		CMD1GG|FP|MC2DN1|NDAXOA|PGL5|PPGL5|SDH1|SDH2|SDHF		obo:civic.gid#gene	
5177	SDHB		CWS2|IP|MC2DN4|PGL4|PPGL4|SDH|SDH1|SDH2|SDHIP		obo:civic.gid#gene	
519	ATP7B		PWD|WC1|WD|WND		obo:civic.gid#gene	
52	MET	Mesenchymal Epithelial Transition MET is a prototypical receptor tyrosine kinase. Its ligand is Hepatocyte Growth Factor (HGF). MET alterations are drivers of human cancer. Amplification and resulting overexpression has been reported in several cancers, and make the receptor's activity independent of HGF. Gene fusions also decouple kinase activity from the cell membrane and render it constitutively active. Finally, exclusion of the juxtamembrane (JM) domain of the kinase by "skipping" of exon 14 activates the kinase. FDA-approved selective MET inhibitors, including tepotinib and capmatinib, have shown efficacy in cancers with exon 14 skipping mutations or MET amplification.	AUTS9|DA11|DFNB97|HGFR|RCCP2|c-Met		obo:civic.gid#gene	
5200	MAP2K4		JNKK|JNKK1|MAPKK4|MEK4|MKK4|PRKMK4|SAPKK-1|SAPKK1|SEK1|SERK1|SKK1		obo:civic.gid#gene	
5210	SRSF2		PR264|SC-35|SC35|SFRS2|SFRS2A|SRp30b		obo:civic.gid#gene	
5225	SGK1		SGK		obo:civic.gid#gene	
524	ATR		FCTCS|FRP1|MEC1|SCKL|SCKL1		obo:civic.gid#gene	
525	ATRX		JMS|MRX52|RAD54|RAD54L|XH2|XNP|ZNF-HX		obo:civic.gid#gene	
533	AXL		ARK|AXL3|JTK11|Tyro7|UFO		obo:civic.gid#gene	
5354	SMARCA2		BAF190|BIS|BRM|NCBRS|SNF2|SNF2L2|SNF2LA|SWI2|Sth1p|hBRM|hSNF2a		obo:civic.gid#gene	
5356	SMARCB1		BAF47|CSS3|INI-1|INI1|MRD15|PPP1R144|RDT|RTPS1|SNF5|SNF5L1|SWNTS1|Sfh1p|Snr1|hSNFS		obo:civic.gid#gene	
5365	SMO		CRJS|FZD11|Gx|PHLS|SMOH		obo:civic.gid#gene	
537	B2M		AMYLD6|IMD43|MHC1D4		obo:civic.gid#gene	
54	EWSR1	Fusions between EWSR1 and multiple 3` partners are regularly identified in soft tissue sarcomas and can aid in differential diagnosis. The fusion product usually contains the N-terminal transcription-activating domain of EWSR1 and the C-terminal DNA-binding domain of the fusion partner, generating a novel transcription factor.	EWS|EWS-FLI1|bK984G1.4		obo:civic.gid#gene	
5409	SOS1		GF1|GGF1|GINGF|HGF|NS4|SOS-1		obo:civic.gid#gene	
5418	SOX10		DOM|PCWH|SOX-10|WS2E|WS4|WS4C		obo:civic.gid#gene	
549	BARD1				obo:civic.gid#gene	
5499	SSTR5		SS-5-R|SST5		obo:civic.gid#gene	
55	TET2		IMD75|KIAA1546|MDS		obo:civic.gid#gene	
550	BAX		BCL2L4		obo:civic.gid#gene	
5514	STAT1		CANDF7|IMD31A|IMD31B|IMD31C|ISGF-3|STAT91		obo:civic.gid#gene	
5516	STAT3		ADMIO|ADMIO1|APRF|HIES		obo:civic.gid#gene	
5519	STAT5B		GHISID2|STAT5		obo:civic.gid#gene	
5520	STAT6		D12S1644|HIES6|IL-4-STAT|STAT6B|STAT6C		obo:civic.gid#gene	
5525	SULT1E1		EST|EST-1|ST1E1|STE		obo:civic.gid#gene	
5534	STK11		LKB1|PJS|hLKB1		obo:civic.gid#gene	
5572	SYK		IMD82|p72-Syk		obo:civic.gid#gene	
5581	TBXT		SAVA|T|TFT		obo:civic.gid#gene	
56	FOXP1		12CC4|HSPC215|MFH|QRF1|hFKH1B		obo:civic.gid#gene	
5627	TBX2		VETD		obo:civic.gid#gene	
56400	COX2		COII|MTCO2		obo:civic.gid#gene	
56415	ND1		MTND1		obo:civic.gid#gene	
5646	TCF3		AGM8|AGM8A|AGM8B|E2A|E47|ITF1|TCF-3|VDIR|bHLHb21|p75		obo:civic.gid#gene	
5649	ZEB1		AREB6|BZP|DELTAEF1|FECD6|NIL2A|PPCD3|TCF8|ZFHEP|ZFHX1A		obo:civic.gid#gene	
5654	TCF19		SC1|TCF-19		obo:civic.gid#gene	
566	BCL6		BCL5|BCL6A|LAZ3|ZBTB27|ZNF51		obo:civic.gid#gene	
567	BCL7A		BCL7|SMARCJ1		obo:civic.gid#gene	
57	REL		C-Rel|HIVEN86A|IMD92		obo:civic.gid#gene	
570	TNFRSF17		BCM|BCMA|CD269|TNFRSF13A		obo:civic.gid#gene	
5717	TEK		CD202B|GLC3E|TIE-2|TIE2|VMCM|VMCM1		obo:civic.gid#gene	
5723	TF		HEL-S-71p|PRO1557|PRO2086|TFQTL1		obo:civic.gid#gene	
5728	TFAP4		AP-4|bHLHc41		obo:civic.gid#gene	
5731	NR2F2		ARP-1|ARP1|CHTD4|COUPTF2|COUPTFB|COUPTFII|NF-E3|SRXX5|SVP40|TFCOUP2		obo:civic.gid#gene	
5734	TFE3		MRXSPF|RCCP2|RCCX1|TFEA|bHLHe33		obo:civic.gid#gene	
5737	TFF3		ITF|P1B|TFI		obo:civic.gid#gene	
5742	TGFA		TFGA		obo:civic.gid#gene	
5752	TGFBR3		BGCAN|betaglycan		obo:civic.gid#gene	
5761	THBS2		EDSCLL3|TSP2		obo:civic.gid#gene	
5777	TIMP1		CLGI|EPA|EPO|HCI|TIMP|TIMP-1		obo:civic.gid#gene	
58	VHL	Von Hippel-Lindau (VHL) disease is characterized by heterozygous germline mutation in VHL gene on chromosome 3p. Patients are predisposed to developing hemangioblastomas of the brain, spinal cord, and retina; renal cysts and clear cell renal cell carcinoma; pheochromocytoma, pancreatic cysts and neuroendocrine tumors; endolymphatic sac tumors; and epididymal and broad ligament cysts. Cerebellar hemangioblastomas may be associated with headache, vomiting, gait disturbances, or ataxia. Spinal hemangioblastomas and related syrinx usually present with pain. Sensory and motor loss may develop with cord compression. Retinal hemangioblastomas may be the initial manifestation of VHL disease and can cause vision loss. Renal cell carcinoma occurs in about 70% of individuals with VHL and is the leading cause of mortality. Pheochromocytomas can be asymptomatic but may cause sustained or episodic hypertension. Pancreatic lesions often remain asymptomatic and rarely cause endocrine or exocrine insufficiency. Endolymphatic sac tumors can cause hearing loss of varying severity, which can be a presenting symptom. Cystadenomas of the epididymis are relatively common. They rarely cause problems, unless bilateral, in which case they may result in infertility. The VHL gene product encodes pVHL, which binds to elongin C, elongin B, cullin-2 and Rbx1. This complex catalyzes the polyubiquitinylation of specific proteins and targets them for degradation by proteosomes. For example, under normoxic conditions, hydroxylated hypoxia-inducble factor alpha subunits (HIFα) binds pVHL targets HIFα for degradation. Under hypoxic conditions, HIF1α is not hydroxylated, pVHL does not bind, and HIF1α subunits accumulate. HIF1α forms heterodimers with HIF1β and activates transcription of a variety of hypoxia-inducible genes (i.e., VEGF, EPO, TGFα, PDGFβ). Likewise, when pVHL is absent or mutated, HIF1α subunits accumulate, resulting in cell proliferation and the neovascularization of tumors characteristic of VHL disease. Pathogenic variants in VHL either prevent its expression (i.e., deletions, frameshifts, nonsense mutations, and splice site mutations) or lead to the expression of an abnormal protein (i.e., missense mutations). Missense mutations that destabilize packing of the alpha-helical domains, decrease the stability of the alpha-beta domain interface, interfere with binding of elongin C and HIF1α, or disrupt hydrophobic core residues result in loss of HIF regulation and are more likely to result in VHL type 1 (no predisposition to pheochromocytoma). Missense mutations that result in pVHL that is normal with respect to HIF regulation are more likely to be associated with VHL with clinical pheochromocytoma. Acquired somatic pathogenic variants in VHL may give rise to sporadic VHL-type tumors (i.e., clear cell RCC and hemangioblastoma) without other associated tumors characteristic of the hereditary disease. It should be noted that >90% of the most common form of kidney cancer (clear cell renal cell carcinoma) are associated with bi-allelic somatic mutation in the VHL gene, and is the rationale for the anti-angiogenic therapy for RCC patients.	HRCA1|RCA1|VHL1|pVHL		obo:civic.gid#gene	
5813	TMPRSS2		PRSS10		obo:civic.gid#gene	
5814	TMSB4X		FX|PTMB4|TB4X|TMSB4		obo:civic.gid#gene	
5828	TNFAIP3		A20|AIFBL1|AISBL|OTUD7C|TNFA1P2		obo:civic.gid#gene	
5845	TOP1		TOPI		obo:civic.gid#gene	
5848	TOP2A		TOP2|TOP2alpha|TOPIIA|TP2A		obo:civic.gid#gene	
5852	TP53BP1		53BP1|TDRD30|p202|p53BP1		obo:civic.gid#gene	
5870	TPT1		HRF|TCTP|p02|p23		obo:civic.gid#gene	
5876	HSP90B1		ECGP|GP96|GRP94|HEL-S-125m|HEL35|TRA1		obo:civic.gid#gene	
588	CEACAM1		BGP|BGP1|BGPI		obo:civic.gid#gene	
59	BCL2		Bcl-2|PPP1R50		obo:civic.gid#gene	
593	PRDM1		BLIMP-1|BLIMP1|PRDI-BF1		obo:civic.gid#gene	
5939	TSPYL1		TSPYL		obo:civic.gid#gene	
594	BLK		MODY11		obo:civic.gid#gene	
5970	TYK2		IMD35|JTK1		obo:civic.gid#gene	
5971	TYMS		DKCD|HST422|TMS|TS		obo:civic.gid#gene	
5972	TYR		ATN|CMM8|OCA1|OCA1A|OCAIA|SHEP3		obo:civic.gid#gene	
5988	UBE2A		HHR6A|MRXS30|MRXSN|RAD6A|UBC2		obo:civic.gid#gene	
6	BRCA1	BRCA1 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.	BRCAI|BRCC1|BROVCA1|FANCS|IRIS|PNCA4|PPP1R53|PSCP|RNF53		obo:civic.gid#gene	
60	IGF2		C11orf43|GRDF|IGF-II|PP9974|SRS3		obo:civic.gid#gene	
6009	UBTF		CONDBA|NOR-90|UBF|UBF-1|UBF1|UBF2		obo:civic.gid#gene	
6023	UGT1A		GNT1|UGT|UGT1|UGT1A@		obo:civic.gid#gene	
6054	KDM6A		KABUK2|UTX|bA386N14.2		obo:civic.gid#gene	
6071	VEGFA		L-VEGF|MVCD1|VEGF|VPF		obo:civic.gid#gene	
6073	VEGFC		Flt4-L|LMPH1D|LMPHM4|VRP		obo:civic.gid#gene	
608	BMP7		OP-1		obo:civic.gid#gene	
61	AURKA		AIK|ARK1|AURA|BTAK|PPP1R47|STK15|STK6|STK7		obo:civic.gid#gene	
6104	WEE1		WEE1A|WEE1hu		obo:civic.gid#gene	
6107	NSD2		KMT3F|KMT3G|MMSET|RAUST|REIIBP|TRX5|WHS|WHSC1		obo:civic.gid#gene	
6119	WNT11		HWNT11		obo:civic.gid#gene	
6143	XPO1		CRM-1|CRM1|emb|exp1		obo:civic.gid#gene	
6144	XRCC1		RCC|SCAR26		obo:civic.gid#gene	
6146	XRCC3		CMM6		obo:civic.gid#gene	
6152	YES1		HsT441|P61-YES|Yes|c-yes		obo:civic.gid#gene	
61745	TMB	Tumor mutational burden (TMB) refers to the total number of genomic alterations (mutations) in a tumor cell. TMB is commonly assessed by sequencing tumor DNA (e.g. panel sequencing, exome sequencing, whole genome sequencing, etc). Genomic alterations of various types are counted and TMB is often reported as mutations per megabase (mut/Mb). Higher or lower TMB values can be associated with clinically actionable information, for instance it is a biomarker for response to checkpoint inhibitor therapy in some tumor cases. Similarly it may indicate tumors with DNA damage repair defects and predict response to therapies that have been shown to be effective for such tumors.	Tumor Mutation Burden		obo:civic.gid#factor	
61746	MSI	DNA mismatch repair (MMR) is a system for recognizing and repairing erroneous insertion errors, deletion, as well as base misincorporation which can arise during DNA replication. It is evolutionarily conserved. Five MMR proteins are mainly responsible for MMR: MutS-Homologs (MSH2, 3, and 6), MutL-Homolog 1 (MLH1), and Post-Meiotic Segregation 2 (PMS2). MMR deficiency can lead to microsatellite instability (MSI). MSI involves insertion or deletion of short sequences of DNA at microsatellite sequences, which are repetitive di-, tri- or tetranucleotides distributed over the genome. MSI can occur in multiple cancers including colorectal cancer and other gastrointestinal cancers, endometrial cancer, breast cancer, prostate cancer, and bladder cancer. MSI has been associated to better prognosis in colorectal cancer, and also reported to be associated with sensitivity to checkpoint inhibition therapy in some instances.	Microsatellite Instability|dMMR		obo:civic.gid#factor	
61747	Kataegis	Kataegis is a phenomenon characterized by localized clustering of mutations, with other non-random features such as enrichment of C>T and C>G changes on the same strand, typically ranging from a few to several hundred mutations. APOBEC (apolipo-protein B mRNA editing enzyme, catalytic polypeptide-like) enzymes are considered to have a likely role in driving kataegis in non-B cell tumors and AID (activation-induced cytidine deaminase) has been implicated in B cell tumors. Kataegis is seen in ~50% of breast tumors but has also been observed at high frequency in pan-cancer studies overall and across many individual tumor types.	clustered mutagenesis|mutation storms		obo:civic.gid#factor	
61748	CK		Complex Karyotype		obo:civic.gid#factor	
61749	Chromothripsis	Chromothripsis is presumed to occur from a single cataclysmic one-off rearrangement affecting many parts of the genome, and generating extensive genomic rearrangements. It can occur in cancer cells and in patients with congenital disease. It results in extensive DNA damage, involving tens to hundreds of DNA double-strand breaks. Next generation sequencing techniques have enabled the discovery and identification of chromothripsis. It can result in multiple loss or gain of sequence fragments and lead to breaking of tumor suppressor function, or oncogene activation via gene fusion or other mechanisms. Recent data indicate that it may be more widespread than previously realized. Some proposed mechanisms that drive chromothripsis are DNA damage to condensed chromosomes, shortened telomeres, and premature chromosome compaction before DNA replication. Chromothripsis has been linked with specific mutational signatures in some cases, and also has been associated with highly aggressive disease and worse outcomes in various tumors.	Chromosome Shattering|Chromothrypsis		obo:civic.gid#factor	
61751	Methylation signature		DNA methylation|DNA methylation signature		obo:civic.gid#factor	
61752	HPV	HPV can drive multiple types of cancer, including oropharyngeal, anal, cervical, penile, and vaginal cancers. Cervical carcinoma is a leading cause of death from cancer worldwide. There are multiple types of HPV virus. High risk HPV subtypes include HPV-16 and HPV-18. Many of the HPV tumorigenic effects are driven by viral proteins E6 and E7. E6 inhibits apoptosis and interacts with proliferative pathways. E7 binds Rb protein, disassociating it from E2F transcription factors, which can drive early entry into S-phase of the cell cycle.	Human Papillomavirus		obo:civic.gid#factor	
61753	MEF2D::CSF1R				obo:civic.gid#fusion	
61754	FGFR2::v				obo:civic.gid#fusion	
61755	EML4::ALK				obo:civic.gid#fusion	
61756	FGFR3::BAIAP2L1				obo:civic.gid#fusion	
61757	v::NRG1				obo:civic.gid#fusion	
61758	v::ABL1				obo:civic.gid#fusion	
61759	AKAP9::BRAF				obo:civic.gid#fusion	
61760	CBFB::MYH11				obo:civic.gid#fusion	
61761	SS18::SSX1				obo:civic.gid#fusion	
61762	SS18::SSX2				obo:civic.gid#fusion	
61763	SS18::SSX4				obo:civic.gid#fusion	
61764	FGFR2::TACC3				obo:civic.gid#fusion	
61765	TMPRSS2::ERG				obo:civic.gid#fusion	
61766	NPM1::ALK				obo:civic.gid#fusion	
61767	RANBP2::ALK				obo:civic.gid#fusion	
61768	DUX4::v				obo:civic.gid#fusion	
61769	EBF1::PDGFRB				obo:civic.gid#fusion	
61770	v::PDGFRA				obo:civic.gid#fusion	
61771	v::PDGFRB				obo:civic.gid#fusion	
61772	PCM1::JAK2				obo:civic.gid#fusion	
61773	FIP1L1::PDGFRA				obo:civic.gid#fusion	
61774	TFG::ROS1				obo:civic.gid#fusion	
61775	CCDC6::RET				obo:civic.gid#fusion	
61776	BRAF::CUL1				obo:civic.gid#fusion	
61777	ZKSCAN1::BRAF				obo:civic.gid#fusion	
61778	EWSR1::DDIT3				obo:civic.gid#fusion	
61779	FUS::DDIT3				obo:civic.gid#fusion	
61780	WWTR1::CAMTA1				obo:civic.gid#fusion	
61781	TNKS2::PDGFRA				obo:civic.gid#fusion	
61782	FGFR2::BICC1				obo:civic.gid#fusion	
61783	FGFR2::AHCYL1				obo:civic.gid#fusion	
61784	SQSTM1::NTRK1				obo:civic.gid#fusion	
61785	ETV6::NTRK3				obo:civic.gid#fusion	
61786	KIF5B::RET				obo:civic.gid#fusion	
61787	AGK::BRAF				obo:civic.gid#fusion	
61788	PAPSS1::BRAF				obo:civic.gid#fusion	
61789	TRIM24::BRAF				obo:civic.gid#fusion	
61790	v::NTRK3				obo:civic.gid#fusion	
61791	LMNA::NTRK1				obo:civic.gid#fusion	
61792	KMT2A::MLLT3				obo:civic.gid#fusion	
61793	PAX8::PPARG				obo:civic.gid#fusion	
61794	PPFIBP2::BRAF				obo:civic.gid#fusion	
61795	KIAA1549::BRAF				obo:civic.gid#fusion	
61796	EWSR1::FLI1				obo:civic.gid#fusion	
61797	CLTC::ALK				obo:civic.gid#fusion	
61798	CTLA4::CD28				obo:civic.gid#fusion	
61799	ACTB::GLI1				obo:civic.gid#fusion	
61800	DNAJB1::PRKACA				obo:civic.gid#fusion	
61801	PML::RARA				obo:civic.gid#fusion	
61802	BCR::ABL1				obo:civic.gid#fusion	
61803	FGFR2::OGA				obo:civic.gid#fusion	
61804	SLC3A2::NRG1				obo:civic.gid#fusion	
61805	SDC4::NRG1				obo:civic.gid#fusion	
61806	EGFR::RAD51				obo:civic.gid#fusion	
61807	KMT2E::ASNS				obo:civic.gid#fusion	
61808	STRN::ALK				obo:civic.gid#fusion	
61809	MACF1::BRAF				obo:civic.gid#fusion	
61810	CUX1::BRAF				obo:civic.gid#fusion	
61811	STRN::NTRK2				obo:civic.gid#fusion	
61812	PDE4DIP::NTRK1				obo:civic.gid#fusion	
61813	FGFR3::TACC3				obo:civic.gid#fusion	
61814	P2RY8::CRLF2				obo:civic.gid#fusion	
61815	EWSR1::NR4A3				obo:civic.gid#fusion	
61816	TRIM63::NTRK1				obo:civic.gid#fusion	
61817	DDR2::NTRK1				obo:civic.gid#fusion	
61818	GON4L::NTRK1				obo:civic.gid#fusion	
61819	ETV6::NTRK2				obo:civic.gid#fusion	
61820	ETV6::ABL1				obo:civic.gid#fusion	
61821	AGGF1::PDGFRB				obo:civic.gid#fusion	
61822	HEY1::NCOA2				obo:civic.gid#fusion	
61823	PAX3::FOXO1				obo:civic.gid#fusion	
61824	PAX7::FOXO1				obo:civic.gid#fusion	
61826	NUP98::NSD1				obo:civic.gid#fusion	
61827	CBFA2T3::GLIS2				obo:civic.gid#fusion	
61828	ATF7IP::PDGFRB				obo:civic.gid#fusion	
61829	v::BRAF				obo:civic.gid#fusion	
61830	v::NTRK2				obo:civic.gid#fusion	
61831	FAM131B::BRAF				obo:civic.gid#fusion	
61832	NUP214::ABL1				obo:civic.gid#fusion	
61833	SSBP2::JAK2				obo:civic.gid#fusion	
61834	IGH::CRLF2				obo:civic.gid#fusion	
61835	MYB::GATA1				obo:civic.gid#fusion	
61836	SNX2::ABL1				obo:civic.gid#fusion	
61837	FOXP1::ABL1				obo:civic.gid#fusion	
61838	PTK2B::KDM6A				obo:civic.gid#fusion	
61839	PTK2B::STAG2				obo:civic.gid#fusion	
61840	DGKH::ZFAND3				obo:civic.gid#fusion	
61841	IL2RB::MYH9				obo:civic.gid#fusion	
61842	DEK::AFF2				obo:civic.gid#fusion	
61843	KIF5B::MET				obo:civic.gid#fusion	
61844	FGFR1OP2::FGFR1				obo:civic.gid#fusion	
61845	EML6::ALK				obo:civic.gid#fusion	
61846	CAD::ALK				obo:civic.gid#fusion	
61847	GOPC::ROS1				obo:civic.gid#fusion	
61848	CD74::NRG1				obo:civic.gid#fusion	
61849	APP::NRG1				obo:civic.gid#fusion	
61850	NAB2::STAT6				obo:civic.gid#fusion	
61851	KMT2A::v				obo:civic.gid#fusion	
61852	TMPRSS2::ETV1				obo:civic.gid#fusion	
61853	ATF7IP::JAK2				obo:civic.gid#fusion	
61854	EBF1::JAK2				obo:civic.gid#fusion	
61855	PPFIBP1::JAK2				obo:civic.gid#fusion	
61856	STRN3::JAK2				obo:civic.gid#fusion	
61857	TPR::JAK2				obo:civic.gid#fusion	
61858	ETV6::JAK2				obo:civic.gid#fusion	
61859	BCR::JAK2				obo:civic.gid#fusion	
61860	PAX5::JAK2				obo:civic.gid#fusion	
61861	TERF2::JAK2				obo:civic.gid#fusion	
61862	USP25::JAK2				obo:civic.gid#fusion	
61863	ZNF274::JAK2				obo:civic.gid#fusion	
61864	RFX3::JAK2				obo:civic.gid#fusion	
61865	NRF1::BRAF				obo:civic.gid#fusion	
61866	MET::ATXN7L1				obo:civic.gid#fusion	
61867	v::ABL2				obo:civic.gid#fusion	
61868	EWSR1::WT1				obo:civic.gid#fusion	
61869	v::JAK2				obo:civic.gid#fusion	
61870	LPP::HMGA2				obo:civic.gid#fusion	
61871	HMGA2::LPP				obo:civic.gid#fusion	
61872	BCR::PDGFRA				obo:civic.gid#fusion	
61873	COL1A1::PDGFB				obo:civic.gid#fusion	
61874	OFD1::JAK2				obo:civic.gid#fusion	
61875	SMU1::JAK2				obo:civic.gid#fusion	
61876	SNX29::JAK2				obo:civic.gid#fusion	
61877	ZNF430::JAK2				obo:civic.gid#fusion	
61878	TPM3::NTRK1				obo:civic.gid#fusion	
61879	v::RET				obo:civic.gid#fusion	
61880	ATP1B1::NRG1				obo:civic.gid#fusion	
61881	EWSR1::ATF1				obo:civic.gid#fusion	
61882	NUP98::KDM5A				obo:civic.gid#fusion	
61884	RUNX1::RUNX1T1				obo:civic.gid#fusion	
61885	TLX3::BCL11B				obo:civic.gid#fusion	
61886	ETV6::RUNX1				obo:civic.gid#fusion	
61887	KANK1::NTRK2				obo:civic.gid#fusion	
61888	RBPMS::MET				obo:civic.gid#fusion	
61889	GOLGA5::JAK2				obo:civic.gid#fusion	
61890	BCOR::CCNB3				obo:civic.gid#fusion	
61891	CIC::DUX4				obo:civic.gid#fusion	
61892	RANBP2::ABL1				obo:civic.gid#fusion	
61893	ZMIZ1::ABL1				obo:civic.gid#fusion	
61894	CENPC::ABL1				obo:civic.gid#fusion	
61895	NUP153::ABL1				obo:civic.gid#fusion	
61896	LSM14A::ABL1				obo:civic.gid#fusion	
61897	SFPQ::ABL1				obo:civic.gid#fusion	
61898	BAG4::FGFR1				obo:civic.gid#fusion	
61899	TBL1XR1::CSF1R				obo:civic.gid#fusion	
61900	TPR::NTRK1				obo:civic.gid#fusion	
61901	TAF15::ZNF384				obo:civic.gid#fusion	
61902	PAG1::ABL2				obo:civic.gid#fusion	
61903	RCSD1::ABL2				obo:civic.gid#fusion	
61904	KMT2A::ABI1				obo:civic.gid#fusion	
61905	SSBP2::CSF1R				obo:civic.gid#fusion	
61906	ZC3HAV1::ABL2				obo:civic.gid#fusion	
61907	ASPSCR1::TFE3				obo:civic.gid#fusion	
61908	ETV6::NTRK1				obo:civic.gid#fusion	
61909	VCL::NTRK2				obo:civic.gid#fusion	
61910	AFAP1::NTRK2				obo:civic.gid#fusion	
61911	v::TFE3				obo:civic.gid#fusion	
61912	G3BP2::KIT				obo:civic.gid#fusion	
61913	FGFR3::v				obo:civic.gid#fusion	
61914	IGH::EPOR				obo:civic.gid#fusion	
61915	OCLN::RASGRF1				obo:civic.gid#fusion	
61916	SH3PXD2A::HTRA1				obo:civic.gid#fusion	
61917	CIC::LEUTX				obo:civic.gid#fusion	
61918	MAP3K8::v				obo:civic.gid#fusion	
61919	QKI::RAF1				obo:civic.gid#fusion	
61920	KANK4::ALK				obo:civic.gid#fusion	
61922	EGFR::SEPTIN14				obo:civic.gid#fusion	
61923	VOPP1::EGFR				obo:civic.gid#fusion	
61924	SEC61G::EGFR				obo:civic.gid#fusion	
61925	NTRK3::SCAPER				obo:civic.gid#fusion	
61926	SCP2::NTRK1				obo:civic.gid#fusion	
61928	EGFR::PURB				obo:civic.gid#fusion	
61929	EGFR::PPARGC1A				obo:civic.gid#fusion	
61930	EGFR::ZNF713				obo:civic.gid#fusion	
61932	EGFR::BRAF				obo:civic.gid#fusion	
61933	EML4::NTRK3				obo:civic.gid#fusion	
61934	KIF5B::EGFR				obo:civic.gid#fusion	
61935	ERC1::ALK				obo:civic.gid#fusion	
61936	IGHA1::FGFR3				obo:civic.gid#fusion	
61937	MYB::QKI				obo:civic.gid#fusion	
61938	CHD7::BEND2				obo:civic.gid#fusion	
61940	EGFR::VSTM2A				obo:civic.gid#fusion	
61941	EGFR::WIF1				obo:civic.gid#fusion	
61942	HIP1::ALK				obo:civic.gid#fusion	
61943	FBXO11::ALK				obo:civic.gid#fusion	
61944	EGFR::YAP1				obo:civic.gid#fusion	
61946	EGFR::ZNF880				obo:civic.gid#fusion	
61947	FN1::ALK				obo:civic.gid#fusion	
61948	TPM4::ALK				obo:civic.gid#fusion	
61949	DCTN1::ALK				obo:civic.gid#fusion	
61950	ZMYM2::FGFR1				obo:civic.gid#fusion	
61951	BCR::FGFR1				obo:civic.gid#fusion	
61952	TRIM24::FGFR1				obo:civic.gid#fusion	
61954	ZFTA::RELA				obo:civic.gid#fusion	
61955	ZFTA::NCOA1				obo:civic.gid#fusion	
61956	ZFTA::NCOA2				obo:civic.gid#fusion	
61957	ZFTA::MAML2				obo:civic.gid#fusion	
61958	MN1::ZFTA				obo:civic.gid#fusion	
61959	QKI::NTRK2				obo:civic.gid#fusion	
61961	ESR1::CCDC170				obo:civic.gid#fusion	
61963	YAP1::TFE3				obo:civic.gid#fusion	
61964	v::NCOA2				obo:civic.gid#fusion	
61965	CRTC1::MAML2				obo:civic.gid#fusion	
61966	CRTC3::MAML2				obo:civic.gid#fusion	
61967	FUS::ERG				obo:civic.gid#fusion	
61968	FUS::FEV				obo:civic.gid#fusion	
61969	EWSR1::ERG				obo:civic.gid#fusion	
61970	EWSR1::NFATC2				obo:civic.gid#fusion	
61971	FUS::NFATC2				obo:civic.gid#fusion	
61972	FGFR2::?				obo:civic.gid#fusion	
61973	FGFR2::KIAA1217				obo:civic.gid#fusion	
61974	TNIP1::PDGFRB				obo:civic.gid#fusion	
61975	FGFR2::POC1B				obo:civic.gid#fusion	
61976	FGFR2::DBP				obo:civic.gid#fusion	
61977	FGFR2::FILIP1				obo:civic.gid#fusion	
61978	FGFR1::TACC1				obo:civic.gid#fusion	
61979	FGFR1::PLAG1				obo:civic.gid#fusion	
61980	FGFR2::NRAP				obo:civic.gid#fusion	
61981	FGFR2::WAC				obo:civic.gid#fusion	
61982	FGFR2::TNS1				obo:civic.gid#fusion	
61983	FGFR2::TTC28				obo:civic.gid#fusion	
61984	FGFR2::CCDC6				obo:civic.gid#fusion	
61985	SLC4A4::ROS1				obo:civic.gid#fusion	
61986	v::TFEB				obo:civic.gid#fusion	
61987	UFD1::NTRK2				obo:civic.gid#fusion	
61988	RALGPS2::NTRK3				obo:civic.gid#fusion	
61989	TCF3::PBX1				obo:civic.gid#fusion	
61990	EMILIN2::PDGFD				obo:civic.gid#fusion	
61991	SPECC1L::NTRK3				obo:civic.gid#fusion	
61992	EEF1G::ROS1				obo:civic.gid#fusion	
61993	EML1::NTRK2				obo:civic.gid#fusion	
61994	YAP1::MAMLD1				obo:civic.gid#fusion	
61995	YAP1::FAM118B				obo:civic.gid#fusion	
61996	YAP1::v				obo:civic.gid#fusion	
61997	VPS18::NTRK3				obo:civic.gid#fusion	
61998	CD74::ROS1				obo:civic.gid#fusion	
61999	BCR::NTRK2				obo:civic.gid#fusion	
62	PBRM1		BAF180|PB1|RCC|SMARCH1		obo:civic.gid#gene	
62000	v::NUTM1				obo:civic.gid#fusion	
62001	BRD4::NUTM1				obo:civic.gid#fusion	
62002	EWSR1::CREB3L1				obo:civic.gid#fusion	
62003	FUS::CREB3L2				obo:civic.gid#fusion	
62004	MALAT1::GLI1				obo:civic.gid#fusion	
62005	MN1::BEND2				obo:civic.gid#fusion	
62006	MNX1::ETV6				obo:civic.gid#fusion	
62007	DEK::NUP214				obo:civic.gid#fusion	
62008	NPM1::MLF1				obo:civic.gid#fusion	
62009	SDC4::ROS1				obo:civic.gid#fusion	
62010	NFASC::NTRK1				obo:civic.gid#fusion	
62011	ETV6::FGFR3				obo:civic.gid#fusion	
62012	v::DUX4				obo:civic.gid#fusion	
62013	GOLGA4::RAF1				obo:civic.gid#fusion	
62014	ANO10::RAF1				obo:civic.gid#fusion	
62015	IQGAP1::RASGRF1				obo:civic.gid#fusion	
62016	BCOR::MAML3				obo:civic.gid#fusion	
62017	v::MITF				obo:civic.gid#fusion	
62018	VCP::TFE3				obo:civic.gid#fusion	
62019	YWHAE::NUTM2A				obo:civic.gid#fusion	
62020	YWHAE::NUTM2B				obo:civic.gid#fusion	
62021	YWHAE::NUTM2E				obo:civic.gid#fusion	
62022	KAT6A::CREBBP				obo:civic.gid#fusion	
62023	FOS::v				obo:civic.gid#fusion	
62024	v::ALK				obo:civic.gid#fusion	
62025	v::FGFR1				obo:civic.gid#fusion	
62026	v::NTRK1				obo:civic.gid#fusion	
62027	RCSD1::ABL1				obo:civic.gid#fusion	
62028	v::ROS1				obo:civic.gid#fusion	
62029	MIGA1::BRAF				obo:civic.gid#fusion	
62030	RBM15::MRTFA				obo:civic.gid#fusion	
62031	KMT2A::AFDN				obo:civic.gid#fusion	
62032	KMT2A::MLLT10				obo:civic.gid#fusion	
62033	CEP43::FGFR1				obo:civic.gid#fusion	
62034	VGLL2::v				obo:civic.gid#fusion	
62035	KIF5B::FGFR1				obo:civic.gid#fusion	
62037	SERPINE1::FOSB				obo:civic.gid#fusion	
62038	SLC4A4::RASGRF1				obo:civic.gid#fusion	
62039	CD72::ROS1				obo:civic.gid#fusion	
62040	EGFR::FGFR1				obo:civic.gid#fusion	
62041	CLIP2::EGFR				obo:civic.gid#fusion	
62043	MYB::NFIB				obo:civic.gid#fusion	
62045	MEF2D::v				obo:civic.gid#fusion	
62047	MEF2D::BCL9				obo:civic.gid#fusion	
62051	v::IRF4				obo:civic.gid#fusion	
62052	TCF3::HLF				obo:civic.gid#fusion	
62053	IGH::IL3				obo:civic.gid#fusion	
62054	IGH::DUX4				obo:civic.gid#fusion	
62055	v::TFCP2				obo:civic.gid#fusion	
62056	FUS::TFCP2				obo:civic.gid#fusion	
62058	v::NR4A3				obo:civic.gid#fusion	
62060	EGFR::SHC1				obo:civic.gid#fusion	
62061	EGFR::MACF1				obo:civic.gid#fusion	
62062	EGFR::GNAT3				obo:civic.gid#fusion	
62064	EGFR::ERBB4				obo:civic.gid#fusion	
62065	NUP98::v				obo:civic.gid#fusion	
62066	IGH::MYC				obo:civic.gid#fusion	
62067	EGFR::SUMF2				obo:civic.gid#fusion	
62068	C19MC	The C19MC miRNA cluster is a microRNA cluster consisting of several genes (>40 genes, >50 miRNAs). The region is ~100 kb in size on chromosome 19.	C19MC MicroRNA Cluster		obo:civic.gid#factor	
62070	TRPS1::PLAG1				obo:civic.gid#fusion	
62071	EGFR::USP42				obo:civic.gid#fusion	
62072	PICALM::MLLT10				obo:civic.gid#fusion	
62073	LANCL2::EGFR				obo:civic.gid#fusion	
62076	v::ZNF384				obo:civic.gid#fusion	
62078	ZEB2::PDGFRB	The ZEB2::PDGFRB Fusion has been reported in two Ph-Like B-ALL patients. The fusions were in frame. In one patient the exon structure was reported as exon 9 of ZEB2 joined to exon 9 of PDGFRB, removing PDGFRB Extracellular Domains 1-4. In one patient, the fusion occurred together with PAX5::BZW1. One preclinical report indicates that the fusion has driver properties and may respond to imatinib or dasatinib.	ZEB2-PDGFRB		obo:civic.gid#fusion	
62079	PAX5::BZW1				obo:civic.gid#fusion	
625	ZFP36L1		BRF1|Berg36|ERF-1|ERF1|RNF162B|TIS11B|cMG1		obo:civic.gid#gene	
6281	ZNF217		ZABC1		obo:civic.gid#gene	
63	EZH2		ENX-1|ENX1|EZH2b|KMT6|KMT6A|WVS|WVS2		obo:civic.gid#gene	
6317	BTG2		APRO1|PC3|TIS21		obo:civic.gid#gene	
6329	CXCR4		CD184|D2S201E|FB22|HM89|HSY3RR|LAP-3|LAP3|LCR1|LESTR|NPY3R|NPYR|NPYRL|NPYY3R|WHIM|WHIMS|WHIMS1		obo:civic.gid#gene	
634	KLF5		BTEB2|CKLF|IKLF		obo:civic.gid#gene	
6340	USP7		C16DELp13.2|DEL16P13.2|HAFOUS|HAUSP|TEF1		obo:civic.gid#gene	
638	BTG1		APRO2		obo:civic.gid#gene	
6380	TFEB		ALPHATFEB|BHLHE35|TCFEB		obo:civic.gid#gene	
6394	AIMP2		HLD17|JTV-1|JTV1|P38		obo:civic.gid#gene	
64	KMT2D		AAD10|ALR|BCAHH|CAGL114|KABUK1|KMS|MLL2|MLL4|TNRC21		obo:civic.gid#gene	
65	BTK		AGMX1|AT|ATK|BPK|IGHD3|IMD1|PSCTK1|XLA		obo:civic.gid#gene	
6523	LZTR1		BTBD29|LZTR-1|NS10|NS2|SWNTS2		obo:civic.gid#gene	
6534	ZRSR2		U2AF1-RS2|U2AF1L2|U2AF1RS2|URP|ZC3H22		obo:civic.gid#gene	
6538	KDM5C		DXS1272E|JARID1C|MRX13|MRXJ|MRXSCJ|MRXSJ|SMCX|XE169		obo:civic.gid#gene	
6559	ARID1A		B120|BAF250|BAF250a|BM029|C1orf4|CSS2|ELD|MRD14|OSA1|P270|SMARCF1|hELD|hOSA1		obo:civic.gid#gene	
6572	AXIN2		AXIL|ODCRCS		obo:civic.gid#gene	
6590	H2AC6		H2A/l|H2AFL|HIST1H2AC|dJ221C16.4		obo:civic.gid#gene	
6592	H2AC17		H2A.1|H2A/n|H2AC11|H2AC13|H2AC15|H2AC16|H2AFN|HIST1H2AM|dJ193B12.1		obo:civic.gid#gene	
66	APC		BTPS2|DESMD|DP2|DP2.5|DP3|GS|PPP1R46		obo:civic.gid#gene	
6614	H3C2		H3/l|H3C1|H3C10|H3C11|H3C12|H3C3|H3C4|H3C6|H3C7|H3C8|H3FL|HIST1H3B		obo:civic.gid#gene	
6652	SPOP		BTBD32|NEDMACE|NEDMIDF|NSDVS1|NSDVS2|TEF2		obo:civic.gid#gene	
6676	RAD54L		HR54|RAD54A|hHR54|hRAD54		obo:civic.gid#gene	
67	AR		AIS|AR8|DHTR|HUMARA|HYSP1|KD|NR3C4|SBMA|SMAX1|TFM		obo:civic.gid#gene	
6772	LGR5		FEX|GPR49|GPR67|GRP49|HG38		obo:civic.gid#gene	
68	ASXL1		BOPS|MDS		obo:civic.gid#gene	
6856	SOCS1		AISIMD|CIS1|CISH1|JAB|SOCS-1|SSI-1|SSI1|TIP-3|TIP3		obo:civic.gid#gene	
6862	IRS2		IRS-2		obo:civic.gid#gene	
69	ATM	Ataxia-telangiectasia (A-T) is a recessive disorder resulting from germline mutation of the A-T mutated (ATM) gene on chromosome 11q. Upon sensing double-stranded breaks (DSB), the wild-type kinase encoded by ATM initiates the DNA-damage response by phosphorylating histone H2AX and, subsequently, various other proteins, such as BRCA1 and the MRE11–RAD50–NBS1 (MRN) complex, which are recruited to the damaged site. Additionally, ATM phosphorylates p53, resulting in expression of the cyclin-dependent kinase inhibitor p21 and leading to senescence or apoptosis. Somatic variants can result in inhibition or loss of these functions and can cause resistance to therapies that rely on inducing apoptosis via DSBs. Germline variants in A-T patients result in a predisposition to cancer, most frequently hematologic or breast. PARP inhibition has been studied for its potential in treating ATM mutated breast cancer patients.	AT1|ATA|ATC|ATD|ATDC|ATE|TEL1|TELO1		obo:civic.gid#gene	
6906	ABCC3		ABC31|EST90757|MLP2|MOAT-D|MRP3|cMOAT2		obo:civic.gid#gene	
6945	TNFRSF14		ATAR|CD270|HVEA|HVEM|LIGHTR|TR2		obo:civic.gid#gene	
7	BRCA2	BRCA2 mutations in the germline have become a hallmark for hereditary breast and ovarian cancers. Variants that have been demonstrated to reduce the function of the protein have been shown to increase the risk for these cancers, as well as prostate and pancreatic cancer. These findings have been the impetus for the increased popularity of genetic testing of healthy individuals to assess risk. Recent studies in ovarian cancer have also demonstrated that BRCA mutation status can predict treatment response. A number of trials assessing BRCA mutation status have shown an improved response to platinum agents, and more recently has led to the FDA-approval of PARP inhibitors for BRCA-positive ovarian cancers. These studies have resulted in the Society of Gynecologic Oncology to recommend germline BRCA testing in all patients with a diagnosis of ovarian cancer.	BRCC2|BROVCA2|FACD|FAD|FAD1|FANCD|FANCD1|GLM3|PNCA2|XRCC11		obo:civic.gid#gene	
70	BAP1	BAP1 is a deubiquitylase thought to be a key regulator of many cancer-associated pathways. Germline alterations in BAP1 have been characterized as predisposing variants to familial melanocytic skin tumors. These alterations also have been linked to the development of mesothelioma, uveal melanoma, cutaneous melanoma and others. Clinically, the role of BAP1 is still being investigated. However, the development of intradermal tumors known as melanocytic BAP1-associated intradermal tumors (MBAITs) are enough for a patient to be subject to more intense surveillance to catch other malignancies as early as possible.	HUCEP-13|KURIS|TPDS1|UBM2|UCHL2|UVM2|hucep-6		obo:civic.gid#gene	
7009	CFLAR		CASH|CASP8AP1|CLARP|Casper|FLAME|FLAME-1|FLAME1|FLIP|I-FLICE|MRIT|c-FLIP|c-FLIPL|c-FLIPR|c-FLIPS|cFLIP		obo:civic.gid#gene	
7014	PROM1		AC133|CD133|CORD12|MCDR2|MSTP061|PROML1|RP41|STGD4		obo:civic.gid#gene	
7024	ALDH1A2		DIH4|RALDH(II)|RALDH2|RALDH2-T		obo:civic.gid#gene	
7041	SPHK1		SPHK		obo:civic.gid#gene	
7044	FUBP1		FBP|FUBP|hDH V		obo:civic.gid#gene	
7074	BCL10		CARMEN|CIPER|CLAP|IMD37|c-E10|mE10		obo:civic.gid#gene	
7084	MBD4		MED1|TPDS2|UVM1		obo:civic.gid#gene	
71	ERG		LMPHM14|erg-3|p55		obo:civic.gid#gene	
72	FOXL2		BPES|BPES1|PFRK|PINTO|POF3		obo:civic.gid#gene	
7222	CCNE2		CYCE2		obo:civic.gid#gene	
7282	AURKB		AIK2|AIM-1|AIM1|ARK-2|ARK2|AurB|IPL1|PPP1R48|STK-1|STK12|STK5|aurkb-sv1|aurkb-sv2		obo:civic.gid#gene	
7297	PTTG1		EAP1|ECRAR|HPTTG|PTTG|TUTR1		obo:civic.gid#gene	
73	IKZF1		CVID13|Hs.54452|IK1|IKAROS|LYF1|LyF-1|PPP1R92|PRO0758|ZNFN1A1		obo:civic.gid#gene	
732	CALR		CALR1|CRT|HEL-S-99n|RO|SSA|cC1qR		obo:civic.gid#gene	
7339	S1PR2		AGR16|DFNB68|EDG-5|EDG5|Gpcr13|H218|LPB2|S1P2		obo:civic.gid#gene	
7351	CD83		BL11|HB15		obo:civic.gid#gene	
7356	KLF4		EZF|GKLF		obo:civic.gid#gene	
74	NCOA3		ACTR|AIB-1|AIB1|CAGH16|CTG26|KAT13B|RAC3|SRC-3|SRC3|TNRC14|TNRC16|TRAM-1|bHLHe42|pCIP		obo:civic.gid#gene	
7411	GRHPR		GLXR|GLYD|PH2		obo:civic.gid#gene	
7451	ABCG2		ABC15|ABCP|BCRP|BCRP1|BMDP|CD338|CDw338|CDw388|EST157481|GOUT1|MRX|MXR|MXR-1|MXR1|UAQTL1		obo:civic.gid#gene	
75	PAX8	PAX8 is one of nine transcription factors within the PAX gene family. It has been observed to be expressed during embryonic development however expression attenuates after development in all but a few tissues. Research has indicated that over-expression of PAX proteins in general are not an initiating event in tumorgenesis however they may facilitate malignant development. PAX8 is expressed in 80-96% of all High-grade serous carcinomas (HGSC) and is commonly used as a marker for the disease. In addition PAX8 has become a useful biomarker for differentiating between mullerian mucinous and non-mullerian tumors. PAX8 has also been associated with neoplasms in the kidney and thyroid.	PAX-8		obo:civic.gid#gene	
7502	KIF23		CDA3|CDAIII|CDAN3|CDAN3A|CHO1|KNSL5|MKLP-1|MKLP1		obo:civic.gid#gene	
76	PGR		NR3C3|PR		obo:civic.gid#gene	
7608	SNCAIP		SYPH1|Sph1		obo:civic.gid#gene	
761	CASP8		ALPS2B|CAP4|Casp-8|FLICE|MACH|MCH5		obo:civic.gid#gene	
77	SMAD4		DPC4|JIP|MADH4|MYHRS		obo:civic.gid#gene	
7704	HDAC9		ARCND4|HD7|HD7b|HD9|HDAC|HDAC7|HDAC7B|HDAC9B|HDAC9FL|HDRP|MITR		obo:civic.gid#gene	
7728	TOX		TOX1		obo:civic.gid#gene	
7777	KEAP1		INrf2|KLHL19		obo:civic.gid#gene	
778	CBL		C-CBL|CBL2|FRA11B|NSLL|RNF55		obo:civic.gid#gene	
7780	CUL7		3M1|CUL-7|KIAA0076|dJ20C7.5		obo:civic.gid#gene	
779	CBLB		ADMIO3|Cbl-b|Nbla00127|RNF56		obo:civic.gid#gene	
78	SMARCA4		BAF190|BAF190A|BRG1|CSS4|MRD16|OTSC12|RTPS2|SNF2|SNF2-beta|SNF2L4|SNF2LB|SWI2|hSNF2b		obo:civic.gid#gene	
79	TERT		CMM9|DKCA2|DKCB4|EST2|PFBMFT1|TCS1|TP2|TRT|hEST2|hTRT		obo:civic.gid#gene	
7909	FGF19				obo:civic.gid#gene	
7936	AKT3		MPPH|MPPH2|PKB-GAMMA|PKBG|PRKBG|RAC-PK-gamma|RAC-gamma|STK-2		obo:civic.gid#gene	
7948	HDAC6		CPBHM|HD6|JM21|KDAC6|PPP1R90		obo:civic.gid#gene	
7953	BCL2L11		BAM|BIM|BOD		obo:civic.gid#gene	
7954	SH2B3		IDDM20|LNK		obo:civic.gid#gene	
8	CCND1	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins, and the cyclin-dependent kinases (CDK's) they activate, have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, but currently there are no FDA-approved targeted therapies.	BCL1|D11S287E|PRAD1|U21B31		obo:civic.gid#gene	
80	TTF1		TTF-1|TTF-I		obo:civic.gid#gene	
8032	RAD50		NBSLD|RAD502|hRad50		obo:civic.gid#gene	
8160	SPRY2		IGAN3|hSPRY2		obo:civic.gid#gene	
8197	MAEA		EMLP|EMP|GID9|HLC-10|P44EMLP|PIG5		obo:civic.gid#gene	
8253	KLF2		LKLF		obo:civic.gid#gene	
826	CD19		B4|CVID3		obo:civic.gid#gene	
8262	TUBB3		CDCBM|CDCBM1|CFEOM3|CFEOM3A|FEOM3|TUBB4|beta-4		obo:civic.gid#gene	
827	MS4A1		B1|Bp35|CD20|CVID5|FMC7|LEU-16|S7		obo:civic.gid#gene	
8292	YAP1		COB1|YAP|YAP-1|YAP2|YAP65|YKI		obo:civic.gid#gene	
8331	MERTK		MER|RP38|Tyro12|c-Eyk|c-mer		obo:civic.gid#gene	
8351	HOXB13		HPC9|PSGD		obo:civic.gid#gene	
8407	AGR2		AG-2|AG2|GOB-4|HAG-2|HEL-S-116|HPC8|PDIA17|RIFTD|XAG-2		obo:civic.gid#gene	
8450	SLCO1B1		HBLRR|LST-1|LST1|OATP-C|OATP1B1|OATP2|OATPC|SLC21A6		obo:civic.gid#gene	
8508	CTCF		CFAP108|FAP108|MRD21		obo:civic.gid#gene	
8516	GNA13		G13|HG1N		obo:civic.gid#gene	
8524	DLL3		SCDO1		obo:civic.gid#gene	
855	CD44		CDW44|CSPG8|ECM-III|ECMR-III|H-CAM|HCELL|HUTCH-1|HUTCH-I|Hermes-1|IN|LHR|MC56|MDU2|MDU3|MIC4|Pgp1		obo:civic.gid#gene	
8552	STAG3		SA3|SPGF61		obo:civic.gid#gene	
8553	STAG2		HPE13|MKMS|NEDXCF|SA-2|SA2|SCC3B|bA517O1.1		obo:civic.gid#gene	
859	CD58		LFA-3|LFA3|ag3		obo:civic.gid#gene	
8614	HSPH1		HSP105|HSP105A|HSP105B|NY-CO-25		obo:civic.gid#gene	
864	CD70		CD27-L|CD27L|CD27LG|LPFS3|TNFSF7|TNLG8A		obo:civic.gid#gene	
868	CD79B		AGM6|B29|IGB|Igbeta		obo:civic.gid#gene	
8787	TLK2		HsHPK|MRD57|PKU-ALPHA		obo:civic.gid#gene	
8813	PIM2				obo:civic.gid#gene	
8878	PTPRT		R-PTP-T|RPTP-rho|RPTPrho		obo:civic.gid#gene	
888	CDH1		Arc-1|BCDS1|CD324|CDHE|ECAD|LCAM|UVO		obo:civic.gid#gene	
8908	PTP4A3		PRL-3|PRL-R|PRL3		obo:civic.gid#gene	
8950	CHEK2		CDS1|CHK2|HuCds1|LFS2|PP1425|RAD53|TPDS4|hCds1		obo:civic.gid#gene	
8996	SP140		LYSP100|LYSP100-A|LYSP100-B		obo:civic.gid#gene	
9	CCND2	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, ranging from genomic amplification to changes in promoter methylation. While Cyclin D2 has only been found to be significantly deregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.	KIAK0002|MPPH3		obo:civic.gid#gene	
9054	RRAS2		NS12|TC21		obo:civic.gid#gene	
906	CDK2		CDKN2|p33(CDK2)		obo:civic.gid#gene	
908	CDK5		LIS7|PSSALRE		obo:civic.gid#gene	
912	CDK9		C-2k|CDC2L4|CTK1|PITALRE|TAK		obo:civic.gid#gene	
9121	ZHX2		AFR1|RAF		obo:civic.gid#gene	
913	CDKN1A		CAP20|CDKN1|CIP1|MDA-6|P21|SDI1|WAF1|p21CIP1		obo:civic.gid#gene	
914	CDKN1B		CDKN4|KIP1|MEN1B|MEN4|P27KIP1		obo:civic.gid#gene	
916	CDKN2B		CDK4I|INK4B|MTS2|P15|TP15|p15INK4b		obo:civic.gid#gene	
9171	DKK1		DKK-1|SK		obo:civic.gid#gene	
9189	NT5C2	This gene, when mutated to be over-active, has been linked to chemotherapy resistance in relapsed T-cell Acute Lymphoblastic Leukemia.	GMP|NT5B|PNT5|SPG45|SPG65|cN-II		obo:civic.gid#gene	
9216	SPEN		HIAA0929|MINT|RATARS|RBM15C|SHARP		obo:civic.gid#gene	
9236	ZNF292		MRD63|MRD64|Nbla00365|ZFP292|ZN-16|Zn-15|bA393I2.3		obo:civic.gid#gene	
9261	SETD1B		IDDSELD|KMT2G|Set1B		obo:civic.gid#gene	
927	CDX2		CDX-3|CDX2/AS|CDX3		obo:civic.gid#gene	
9326	CIC		MRD45		obo:civic.gid#gene	
9427	MGA		MAD5|MXD5		obo:civic.gid#gene	
9533	DICER1		DCR1|Dicer|Dicer1e|GLOW|HERNA|K12H4.8-LIKE|MNG1|RMSE2|aviD		obo:civic.gid#gene	
9538	SIRT1		SIR2|SIR2L1|SIR2alpha		obo:civic.gid#gene	
9588	BRD4		CAP|CDLS6|FSHRG4|HUNK1|HUNKI|MCAP		obo:civic.gid#gene	
9705	CBLC		CBL-3|CBL-SL|RNF57		obo:civic.gid#gene	
9722	PPP1R15A		GADD34		obo:civic.gid#gene	
981	CHEK1		CHK1|OZEMA21		obo:civic.gid#gene	
9935	POT1		CMM10|CRMCC3|GLM9|HPOT1|PFBMFT8|TPDS3		obo:civic.gid#gene	
9957	SIN3A		CHR15DELq24|DEL15Q24|WITKOS		obo:civic.gid#gene	
